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CDC’S DES UPDATE 

Diethylstilbestrol (DES) is a synthetic estrogen that was developed in 1938 to supplement a 
woman’s natural estrogen production.  Prescribed by physicians during 1938–1971 for women 
who experienced miscarriages or premature deliveries, DES was originally considered effective and 
safe for both the pregnant woman and the developing baby.
In the United States, an estimated 5–10 million persons were exposed to DES during 
1938–1971, including women who were prescribed DES while pregnant and the female and male 
children born of these pregnancies.  
The Centers for Disease Control and Prevention (CDC) has developed CDC’s DES Update so 
the public and health care providers have the latest, most comprehensive, and accurate informa­
tion about DES. CDC is working with consumer organizations and health care provider partners 
around the country to distribute information about DES. 
CDC’s DES Update includes: 
� Fact Sheets – Information on the history of DES, known health effects, recent and on-going 
research, tips for working with your health care provider, and steps to take for protecting 
your health and the health of your family. 
� DES Self-Assessment – A guide to help you determine if you might have been exposed to 
DES. 
� DES Health Information Record – A form to help you keep track of your DES health 
information. 
CDC’s DES Update also includes a Web site (www.cdc.gov/DES) from which you can print and 
download information and a toll-free number (1-888-232-6789) that you can call for free printed 
materials. The DES Update is a resource for you, your family, and your health care provider, and 
is designed to help persons who think they may have been exposed to DES stay up-to-date. 
— Centers for Disease Control and Prevention 
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Diethylstilbestrol (DES) is a synthetic estrogen that was developed to supplement a woman’s natu­
ral estrogen production.  First prescribed by physicians in 1938 for women who experienced mis­
carriages or premature deliveries, DES was originally considered effective and safe for both the 
pregnant woman and the developing baby.  In the United States, an estimated 5–10 million per­
sons were exposed to DES during 1938–1971, including women who were prescribed DES while 
pregnant and the female and male children born of these pregnancies.  In 1971, the Food and 
Drug Administration (FDA) issued a Drug Bulletin advising physicians to stop prescribing DES to 
pregnant women because it was linked to a rare vaginal cancer in female offspring. 
More than 30 years of research have confirmed that health risks are associated with DES exposure. 
However, not all exposed persons will experience the following DES-related health problems.  
•  Women prescribed DES while pregnant are at a modestly increased risk for breast cancer. 
•  Women exposed to DES before birth (in the womb), known as DES Daughters, are at an 
increased risk for clear cell adenocarcinoma (CCA) of the vagina and cervix, reproductive tract 
structural differences, pregnancy complications, and infertility.  Although DES Daughters 
appear to be at highest risk for clear cell cancer in their teens and early 20s, cases have been 
reported in DES Daughters in their 30s and 40s (Hatch, 1998). 
•  Men exposed to DES before birth (in the womb), known as DES Sons, are at an increased risk 
for non-cancerous epididymal cysts. 
Researchers are still following the health of persons exposed to DES to determine whether other 
health problems occur as they grow older. 
Whether you know for sure or suspect you were exposed to DES, you can use CDC’s DES Update 
to learn more about what DES exposure means and what you can do about DES.  This section of 
CDC’s DES Update includes the following information. 
• DES: Yesterday, Today, Tomorrow – A history of DES and what to look for about DES in 
the future. 
• CDC’s DES Update – An overview of CDC’s DES health education program, including a 
timeline of the history of DES and a list of partner organizations. 
• CDC’s DES Update in Brief – A summary card to help start a discussion about DES.  Take 
this card to your health care provider and share it with family and friends. 
• Known DES Health Effects – In-depth information about the health effects found in women 
prescribed DES while pregnant, DES Daughters, and DES Sons. 
• Understanding DES Research – Information on DES research, including how to decide 
whether a source of information is reliable, what can be learned about human health risks 
from laboratory animal studies, and the role of cohort studies in DES research. 




DES: YESTERDAY, TODAY, TOMORROW 
DES: Yesterday 
Diethylstilbestrol (DES) is an estrogen that was first manufactured in a laboratory in 1938, so it is 
called a “synthetic estrogen.”  During 1938–1971, U.S. physicians prescribed DES to pregnant 
women to prevent miscarriages and avoid other pregnancy problems.  As a result, an estimated 
5–10 million pregnant women and the children born of these pregnancies were exposed to DES. 
Physicians prescribed DES to pregnant women on the theory that miscarriages and premature 
births occurred because some pregnant women did not produce enough estrogen naturally.  At the 
time, physicians thought DES was safe and would prevent miscarriages and pre-term (early) births.  
In 1953, published research showed that DES did not prevent miscarriages or premature births. 
However, DES continued to be prescribed until 1971.  In that year, the Food and Drug 
Administration (FDA) issued a Drug Bulletin advising physicians to stop prescribing DES to preg­
nant women. The FDA warning was based on a study published in 1971 that identified DES as a 
cause of a rare vaginal cancer in girls and young women who had been exposed to DES before birth 
(in the womb). 
The news that DES could be harmful led to a national effort to find women prescribed DES while 
pregnant and notify them of the potential DES-related health problems.  Physicians reviewed 
patients’ medical records and notified women who had been prescribed DES.  As a result of this 
effort, many women were made aware of the DES health risk known at that time, known as clear 
cell adenocarcinoma (CCA), a rare vaginal cancer.  Women were encouraged to have their DES-
exposed daughters screened regularly by a gynecologist because CCA was found in girls as young as 
8 years old. 
Women contacted during the 1970s, along with their children, formed the core of large study 
groups that researchers call “cohorts.”  Researchers studied the health of these DES-exposed cohorts 
for more than 20 years.  Much of what is known about DES-related health risks is the result of 
these long-term studies. For more information on these cohort studies, refer to the section of 
CDC’s DES Update titled WHAT WE ARE LEARNING ABOUT DES: Recent DES Research. 
Despite earlier efforts to identify DES-exposed women and men, many persons exposed to DES 
were not located.  These persons may not realize that they were exposed to DES.  Unfortunately, no 
medical test (such as blood, urine, or skin analysis) can detect DES exposure.  However, to assess 
whether you may have been exposed to DES and to learn what you can do about DES, refer to the 
sections of CDC’s DES Update titled DES SELF-ASSESSMENT: A Guide to Understanding Your 
Risk for DES Exposure, and WHAT YOU CAN DO ABOUT DES. 
All DES-exposed persons are at an increased risk for developing some health problems when com­
pared with persons who were not exposed to DES.  All of the health problems related to DES 
exposure also can occur in persons who were not exposed to DES.  To learn more, refer to the sec­
tion of CDC’s DES Update titled WHAT WE KNOW ABOUT DES: Known DES Health 
Effects. 
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Many companies manufactured DES and similar synthetic drugs.  In 1976, the Journal of the 
American Medical Association (JAMA) published a list of the most commonly used names and 
spellings for DES and similar drugs. 
DES Type-Drugs That May Have Been Prescribed to Pregnant Women 
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DES: Today 
Over the years, research has shown that exposure to DES puts both women and men at an 
increased risk for certain health problems.  This means that some, but not all, of the women and 
men who were exposed to DES will experience one or more DES-related health problems. 
Research confirms the following increased health risks associated with DES: 
Women Prescribed DES While Pregnant are at a modestly increased risk for 
• Breast cancer 
DES Daughters are at an increased risk for 
• Clear cell adenocarcinoma (CCA), a rare kind of vaginal and cervical cancer 
Increased risk for clear cell cancer appears to be highest for DES Daughters in their 
teens and early 20s. However, case have been reporter for DES Daughters in their 30s 
and 40s (Hatch, 1998). 
• Reproductive tract structural differences (for example, T-shaped uterus) 
• Pregnancy complications, including ectopic (tubal) pregnancy and pre-term (early) delivery 
• Infertility 
DES Sons are at an increased risk for 
• Non-cancerous epididymal cysts (growths on the testicles) 
To learn more about DES-related health risks, refer to the section of CDC’s DES Update titled 
WHAT WE KNOW ABOUT DES: Known DES Health Effects. 
No medical test (such as a blood, urine, or skin analysis) can detect DES exposure.  Tracing old 
medical records that prove DES exposure is difficult.  Understandably, many women do not 
remember whether they were prescribed DES while pregnant.  Physicians who prescribed DES may 
have retired or passed away.  Their records may have been destroyed.  All these factors make it diffi­
cult for persons to determine their DES-exposure status with certainty. 
We do know that women who were not under a physician’s care during their pregnancy likely did 
not receive DES, because it required having a physician’s prescription.  However, sometimes physi­
cians gave DES pills or injections directly to their patients.  We also know that most women who 
were prescribed DES had a history of miscarriage or giving birth prematurely. 
For help deciding whether you might have been exposed to DES, refer to the section of CDC’s 
DES Update titled DES SELF-ASSESSMENT: A Guide to Understanding Your Risk for DES 
Exposure. 
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CDC’S DES UPDATE 
Overview 
The Centers for Disease Control and Prevention (CDC) have developed CDC’s DES Update so the 
public and health care providers have the latest, most comprehensive, and accurate information 
about diethylstilbestrol (DES).   
CDC’s DES Update was funded by the U.S. Congress and developed in conjunction with the 
National Cancer Institute (NCI) and many partner organizations.  Researchers have been studying 
the effects of DES exposure for more than 30 years.  However, not all persons who were exposed to 
DES nor their health care providers have always known the latest information about DES. 
A key goal of CDC’s DES Update is to provide the most comprehensive information about DES, 
including findings from continuing studies on the health effects of DES exposure.  CDC has also 
designed and distributed DES Update educational materials that give health care providers the lat­
est research and tools they can use to learn more about DES.  Ultimately, we want to help patients 
and health care providers have good discussions about DES and make the right choices to protect 
patients’ health. 
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How Can CDC’s DES Update Help Me? 
CDC’s DES Update includes information for persons who want to 
• assess whether they might have been exposed to DES; 
• know more about how exposure to DES could affect them, their family, and friends; 
• stay up-to-date on research about the effects of exposure to DES; 
• get advice about talking with health care providers about DES; 
• share information about DES with others; and 
• contact the DES Update’s partner organizations. 
CDC’s DES Update is a resource for you, your family, and your health care provider.  CDC’s DES 
Update includes a Web site (www.cdc.gov/DES) from which you can print and download informa­
tion, and a toll-free number (1-888-232-6789) that you can call for free printed materials. 
CDC’s DES Update can help persons who think they may have been exposed to DES.  To assess 
whether you may have been exposed to DES and to learn what you can do about DES exposure, 
refer to the section of CDC’s DES Update titled DES SELF-ASSESSMENT: A Guide to 
Understanding Your Risk for DES Exposure. 
CDC will also sponsor a series of teleconferences, during which researchers and clinicians will pres­
ent the latest research on DES exposure.  The public is invited to call in, and DES researchers and 
clinicians will be available to answer questions from callers.  Summaries of the teleconferences will 
be posted on CDC’s DES Update Web site.  For more information about these teleconferences, 
refer to the section of CDC’s DES Update titled WHAT WE ARE LEARNING ABOUT DES: 
DES Teleconferences. 




CDC’S DES UPDATE [ 3 ] 
What is CDC’s DES Update doing to get the word out? 
CDC is working with advocacy and health care provider partners around the country to distribute 
information about DES. For example, DES advocacy organizations (such as DES Action, DES 
Cancer Network, and DES Sons Network) are channels to reach people who know they have been 
exposed to DES. In addition, the National Centers of Excellence in Women’s Health developed 
materials to update health care providers. 
The following government and non-government organizations worked 
with CDC to produce the DES Update: 
American Academy of Physician Assistants 
American College of Nurse-Midwives 
American College of Obstetricians and Gynecologists 
American Medical Association 
American Medical Women’s Association 
American Nurses Association 
Association of Reproductive Health Professionals 
DES Action USA
DES Cancer Network 
DES Sons Network 
Mennonite College of Nursing at Illinois State University 
National Association of Nurse Practitioners in Women’s Health 
National Cancer Institute, National Institutes of Health 
National Centers of Excellence in Women’s Health 
National Women’s Health Network 
Office on Women’s Health, Department of Health and Human 
Services 
Registry for Research on Hormonal Transplacental Carcinogenesis, 
University of Chicago 
RESOLVE: The National Infertility Association 
Y-ME Indianapolis 
Y-ME Chattanooga 
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KNOWN DES HEALTH EFFECTS 
Overview 
Research has confirmed that several health risks are associated with DES exposure.  Risks have been 
identified for women prescribed DES while pregnant; women exposed to DES before birth (in the 
womb), known as DES Daughters; and men exposed to DES before birth (in the womb), known as 
DES Sons.  These risks include: 
Women Prescribed DES While Pregnant are at a modestly increased risk for 
• Breast cancer 
DES Daughters are at an increased risk for 
• Clear cell adenocarcinoma (CCA), a rare kind of vaginal and cervical cancer 
• Reproductive tract structural differences (for example, T-shaped uterus) 
• Pregnancy complications, such as ectopic (tubal) pregnancy and pre-term delivery 
• Infertility  
DES Sons are at an increased risk for 
• Non-cancerous epididymal cysts (growths on the testicles) 
Research continues on the health risks for women and men exposed to DES.  For more informa­
tion, refer to the section of CDC’s DES Update titled WHAT WE ARE LEARNING ABOUT 
DES: Recent DES Research. 
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Women Prescribed DES While Pregnant 
This section addresses questions about increased health risks for women prescribed DES while preg­
nant, including information on 
• their increased risk of breast cancer, and 
• steps that should be taken for detecting breast cancer early. 
I was prescribed DES during my pregnancy.  Am I at an increased risk for any health problems? 
Women prescribed DES while pregnant are at a modestly increased risk for developing breast can­
cer.  Studies have consistently reported an increased risk of approximately 30% for women pre­
scribed DES while pregnant.  The most recent study, published in the British Journal of Cancer 
(Titus-Ernstoff, 2001), included more than 6,000 women and compared breast cancer rates of 
women exposed to DES with rates among women who were not exposed.  This study followed par­
ticipants over a longer period of time than earlier research on breast cancer risks associated with 
DES. The researchers’ findings were consistent with earlier studies, confirming an increased breast 
cancer risk of approximately 30% for women prescribed DES while pregnant.  That means when 
considering breast cancer risks across a lifetime, one in six women prescribed DES during pregnan­
cy will get breast cancer.  In comparison, only one in eight unexposed women will get breast cancer 
across their lifetime. 
Why haven’t I heard about a connection between DES and breast cancer? 
Early studies of women prescribed DES while pregnant were inconclusive.  Even now, not all 
researchers agree that there is a link between DES exposure and breast cancer.  Despite differences 
of opinion, the 2001 British Journal of Cancer study is important for two reasons.  First, it is the 
largest study of its kind. Second, participants in the 2001 study were older than participants in 
previous studies; as women grow older, their chances for developing breast cancer increase, regard­
less of whether they were exposed to DES.  Because participants were older, many more women 
had breast cancer in the 2001 study than in earlier studies.  This provides the 2001 study with 
more “power” to detect meaningful differences between the rates of breast cancer among women 
who were and were not exposed to DES.  In other words, the more women included in a study, the 
less likely that the results of the study can be considered chance.  Now researchers can confirm with 
a higher degree of certainty that women prescribed DES while pregnant have a modestly increased 
risk of breast cancer. 
How does being prescribed DES while pregnant compare with other risk factors for breast cancer? 
Exposure to DES while pregnant is just one of many factors that can increase a woman’s chance of 
developing breast cancer.  Several other factors can further increase the risk for breast cancer,  includ­
ing personal and family history of breast cancer, genetics, diet and lifestyle choices, use of hormone 
replacement therapy (HRT), and having children later in life.  In addition, as women grow older, 
their chances of developing breast cancer increase, regardless of whether they were exposed to DES. 
The following chart explains the increasing risk for breast cancer as a woman ages.  This chart illus­
trates breast cancer risk for women who were not exposed to DES while pregnant. 
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A woman’s chance of being diagnosed with breast cancer: 
from age 30 to age 40. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 out of 257 women 
from age 40 to age 50 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 out of 67 women 
from age 50 to age 60 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 out of 36 women 
from age 60 to age 70 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 out of 28 women 
from age 70 to age 80 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 out of 24 women 
Ever . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 out of 8 women 
* Source: National Cancer Institute Surveillance, Epidemiology, and End Results Program, 1995-1997. 
If I was prescribed DES while pregnant, what can I do now to increase my chances for early
detection of breast cancer? 
You should follow a regular schedule for breast cancer screening recommended by your health care 
provider.  The types and timing of the screening should be based on your risk factors for breast can­
cer.  Talk with your health care provider about when you should start screenings for breast cancer 
and how often you should be checked.  Your health care provider may recommend that you learn 
and practice breast self-examination as a way to detect any lumps in your breasts, discharge from 
the nipples, or skin changes (such as dimpling or puckering). Most health care providers will rec­
ommend that women 40 years of age and older have a mammogram (an X-ray of the breast) every 
1–2 years.  In addition, most health care providers perform clinical breast examinations (visual and 
manual examination of the breast) during routine physical examinations.  
For more information about breast cancer causes and prevention, visit the NCI Web site at 
www.cancer.gov or call the Cancer Information Service (CIS) toll-free 1-800-4-CANCER (1-800­
422-6237). For more information about DES exposure and related health risks, visit CDC’s DES 
Update Web site at www.cdc.gov/DES or call toll-free 1-888-232-6789.  
To learn more about the risk of breast cancer for women prescribed DES while pregnant, refer to 
the sections of CDC’s DES Update titled WHAT WE ARE LEARNING ABOUT DES: Recent 
DES Research and ADDITIONAL DES RESOURCES: DES Bibliography. 
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Women Exposed To DES Before Birth (In The Womb), Known As DES Daughters 
This section addresses general and specific questions about increased health risks for DES 
Daughters, including information on 
• clear cell adenocarcinoma (CCA) of the vagina and cervix; 
• pregnancy complications and infertility; 
• steps to take with your health care provider to minimize your health risks; and 
• what to tell your siblings about DES. 
General Questions about Health Risks 
My mother was prescribed DES while pregnant with me.  Am I at an increased risk for any 
health problems? 
Recent research has confirmed that women exposed to DES before birth (in the womb), known as 
DES Daughters, are at an increased risk for the following health problems: 
• Clear cell adenocarcinoma (CCA) – A rare type of vaginal and cervical cancer. 
Approximately one in 1,000 (0.1 %) DES Daughters might be expected to develop CCA.  
The risk is virtually non-existent among premenopausal women not exposed to DES. 
• Reproductive tract structural differences – Including T-shaped uterus, hooded cervix, cervi­
cal cockscomb, and pseudopolyp. 
• Pregnancy complications – Ectopic (tubal) pregnancy and pre-term (early) delivery. 
• Infertility – Difficulty becoming pregnant. 
The amount of risk for each of these problems varies, and all of these health effects also can occur 
in women not exposed to DES. The following information provides more detail about each of 
these health problems. 
Clear Cell Adenocarcinoma (CCA) of the Vagina and Cervix 
CCA, a rare form of vaginal and cervical cancer, was the first health problem identified as being 
associated with DES exposure (Herbst, 1971; Noller, 1972).  CCA of the vagina and cervix occurs 
more frequently in DES Daughters than in women not exposed to DES.  DES Daughters are 40 
times more likely to develop CCA of the vagina and cervix than women not exposed to DES.  This 
means that approximately one of every 1,000 women exposed to DES before birth (in the womb) 
might be expected to develop CCA of the vagina and/or the cervix. 
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Before the use of DES, CCA of the vagina and cervix only occurred in women past childbearing 
age. In contrast, DES Daughters have been diagnosed with CCA of the vagina and cervix at as 
early as age 8 and up to their late teens and early 20s. In addition, recent studies have indicated 
that some DES Daughters have been diagnosed with CCA of the vagina and cervix in their 30s and 
40s (Hatch, 1998).  Therefore, DES Daughters should have regular cancer screenings as they 
grow older. 
Reproductive Tract Structural Differences 
Some studies have shown that up to one third of DES Daughters were born with or developed 
some form of reproductive tract abnormality of the cervix, uterus, or fallopian tubes, including 
vaginal adenosis or cervical changes (such as collars, hoods, septae, and cockscombs) (Jeffries, 1984; 
Herbst, 1984).  Many of these changes are harmless and had no effect on physical development, 
risk of disease, or ability to conceive a child.  However, some DES Daughters experienced health 
problems as a result of reproductive tract abnormalities.  DES Daughters should talk with their 
health care providers about the possibility of reproductive tract structural differences so they can 
work together to identify and treat any potential problems. 
Pregnancy Complications and Infertility 
Most DES Daughters will be able to conceive and carry a healthy baby to term.  However, DES 
Daughters are at an increased risk of reproductive problems, including complications during preg­
nancy and infertility. 
• Premature Delivery. Consistently, research shows that DES Daughters are at an increased risk 
for problems during pregnancy.  These problems are primarily associated with an increased risk 
for premature (early) delivery.  Of DES Daughters, 64% deliver a full-term baby in their first 
pregnancy, compared with 85% of unexposed women.  Approximately 20% of DES Daughters 
experience pre-term labor, compared with 8% of unexposed women (Kaufman, 2000). 
Important Note on Fertility 
If you are a DES Daughter, it is critical that you tell your health care provider when you begin planning your pregnancy. 
 
Many of the risk factors associated with DES exposure during pregnancy are preventable or treatable if you take action. 
 
Any pregnancy of a DES Daughter should be treated as “high risk” by health care providers.
 
Comparison of Full-term Delivery and Miscarriage Rates for 
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* Kaufman, 2000 
CDC’s DES Update Toll-free 1-888-232-6789 www.cdc.gov/DES 
KNOWN DES HEALTH EFFECTS [ 3 ] 
• Other Pregnancy Complications. DES Daughters are also at an increased risk for other com­
plications during pregnancy, including ectopic (tubal) pregnancy, and miscarriage. Estimates of 
a DES Daughter’s risk for an ectopic pregnancy range from 3–5 times higher than the risk for 
a woman not exposed to DES. DES Daughters are also more likely to experience miscarriage 
than are unexposed women.  The most recent study found almost 20% of DES Daughters had 
a miscarriage during their first pregnancy.  About 10% of unexposed women had a miscarriage 
during their first pregnancy.  The risk of miscarriage during the second trimester is slightly 
higher than the risk of miscarriage during the first trimester.  Overall, 82%–85% of DES 
Daughters were able to deliver at least one healthy baby, compared to 87% of unexposed 
women. DES Daughters were less likely than unexposed women to have more than one child 
(Kaufman, 2000). 
Three Possible Sites of an Ectopic 
Pregnancy in DES Daughters 
The risk of an ectopic pregnancy is 
 
3 to 5 times higher 
 
for a DES Daughter.
 

• Infertility. The most recent and comprehensive infertility study reported that 24% of DES 
Daughters were unable to become pregnant, compared with 18% of women not exposed to 
DES. Additionally, 28% of DES Daughters had tried for 12 months to become pregnant 
without success, compared with 16% of women not exposed to DES.  DES exposure was most 











DES Daughters Unexposed Women 
Infertility Rates for DES Daughters vs. Unexposed Women* 
* Palmer, 2001 
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Specific Questions about Clear Cell Adenocarcinoma (CCA) of the Vagina and Cervix 
I’m in my 40s.  Am I still at risk for CCA of the vagina and cervix? 
So far, most DES-related cases of CCA of the vagina and cervix have occurred in women in their 
late teens and early 20s. However, a small number of DES-related clear cell cancers have been diag­
nosed in women in their 30s and 40s (Hatch, 1998; Herbst, 2000).  In the general population, 
CCA of the vagina and cervix is rare and when found, it occurs in women past childbearing age. 
Because DES Daughters now range in age from their early 30s to early 60s, many have not reached 
or are just approaching menopause.  Currently, researchers do not know whether DES exposure will 
make CCA more common when DES Daughters are past menopause.  Therefore, DES Daughters 
should continue to receive regular cancer screening throughout their lifetimes. 
Are women who were prescribed DES while pregnant at an increased risk for CCA of the vagina 
and cervix? 
No.  The increased risk for CCA of the vagina and cervix only applies to DES Daughters and not 
to women prescribed DES while pregnant. 
What should I expect from my health care provider in terms of detecting and monitoring CCA of 
the vagina and cervix? 
CCA of the vagina and cervix is treatable when detected early.  Therefore, the most important step 
that any woman can take is to continue to receive regular gynecological examinations throughout 
her lifetime. The National Cancer Institute (NCI) published a description of appropriate pelvic 
examinations for DES Daughters.  In this publication, recommendations regarding pelvic examina­
tions for DES Daughters were similar to those recommended for unexposed women.  Special steps 
included 
• Careful visual examination and palpation (feeling) of the vagina and cervix with rotation of the 
speculum so that all vaginal walls can be inspected; 
• Pap smears from the cervix and the surfaces of the upper vagina; and 
• Iodine staining of the vagina and cervix or a colposcopy if abnormalities are detected during 
the examination. 
Iodine staining allows your health care provider to distinguish healthy tissues from 
abnormal ones. 
A colposcopy uses a device that works like a magnifying glass, allowing your health care 
provider to carefully check the vagina and cervix.  Your provider may take photographs 
using the colposcope so that any changes in your condition can be monitored during 
future examinations (Kaufman, 1995). 
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Questions about Reproduction and Infertility 
How likely am I to have problems with fertility if I was exposed to DES? 
Although most DES Daughters can successfully conceive and carry a baby to full term, they experi­
ence infertility more than unexposed women.  The most recent study of infertility among DES 
Daughters reported that 24% had never become pregnant, compared with 18% of unexposed 
women. Of DES Daughters, 28% had tried without success to become pregnant over a period of 
12 months, compared with 16% of unexposed women (Palmer, 2001). 
Why does DES increase my risk for infertility? 
Reasons for DES-related infertility vary.  Recent research indicates that the primary reason for an 
increased risk of infertility among DES Daughters results from abnormalities in the uterus or fal­
lopian tubes that are associated with exposure to DES before birth (in the womb) (Palmer, 2001). 
What can I do as a DES Daughter to protect my health during pregnancy? 
If you are planning a pregnancy, or if you are already pregnant, tell your health care provider about 
your DES exposure.  Before you become pregnant, you may want to discuss your increased risks 
with your health care provider, including the risk of infertility, ectopic (tubal) pregnancy, miscar­
riage, and pre-term (early) delivery. 
Once you become pregnant, your health care provider likely will classify you as having a “high-risk” 
pregnancy.  This means you should be closely monitored for DES-related complications during 
your pregnancy.  Again, most DES Daughters have no problems becoming pregnant or carrying a 
baby to full term.  Although all women should have good prenatal care, it is particularly important 
for DES Daughters. 
If I have structural differences in my reproductive tract, will that influence my ability to con­
ceive and bear children? 
Your risk of experiencing infertility or pregnancy complications depends on what reproductive tract 
structural difference you have.  An “abnormal” structure is not necessarily a faulty one; it could just 
mean that an organ is shaped differently or has an additional feature that is not usually present 
(such as a “collar” on the cervix).  By itself, an abnormality does not necessarily cause infertility or 
complicate a pregnancy.  In one study, for example, researchers found that women with DES-relat­
ed changes in the vagina or cervix achieved the same rate of pregnancy as women without those 
abnormalities (Cousins, 1980). However, other research has indicated that abnormalities in the 
uterus have been associated with an increased rate of ectopic (tubal) pregnancy and miscarriage 
(Kaufman, 1980, 1984). 
What are some examples of physical differences? 
Most physical or structural differences associated with exposure to DES are found in the reproduc­
tive tract, including a “hood” or collar on the cervix, T-shaped uterus, and non-cancerous vaginal 
adenosis. Vaginal adenosis, one of the most common changes experienced by DES Daughters, 
occurs when the vagina has an unusual type of tissue on its surface.  Adenosis is often associated 
with excess mucous in the vagina and can be mistaken for a vaginal infection.  Vaginal adenosis, 
like many DES-related physical changes, is harmless and requires no special treatment.  However, 
health care providers should monitor all DES-related abnormalities for changes over time 
(Kaufman, 1995). 
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Reproductive Tract Differences in DES Daughters 
A normal cervix, and one with a “hood” (right). The inside of a normal and a “T” shaped uterus (right). 
What steps should my health care provider and I take in terms of special screenings or tests 
based on my DES exposure? 
Any pregnant woman who is classified as being “high-risk” because of DES exposure or any other 
reason should work with her health care provider to establish a plan of action based on her 
increased health risks.  Preconception counseling with your OB/GYN will help you learn about the 
risks of infertility and pregnancy complications including ectopic (tubal) pregnancy, miscarriage, 
premature labor, and premature birth.  No single test, treatment, or screening is needed because of 
your exposure to DES, but your health care provider may recommend that you undergo certain 
tests or screenings appropriate for your risks.  Some example procedures given to “high-risk” 
women during pregnancy and preconception examinations include 






• if you have experienced infertility, a hysterosalpingogram, which is an X-ray that can check for 
structural differences and physical alterations in your upper genital tract. 
My younger sisters/brothers are worried that they were exposed to DES, even though my mom 
was only prescribed DES when she was pregnant with me.  What can I tell them? 
Only children who were in the womb at the time their mother was prescribed DES are considered 
to have been exposed to DES. 
To learn more about the increased health risks for DES Daughters, refer to the sections of CDC’s 
DES Update titled WHAT WE ARE LEARNING ABOUT DES: Recent DES Research and 
ADDITIONAL DES RESOURCES: DES Bibliography. 
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KNOWN DES HEALTH EFFECTS 
Men Exposed To DES Before Birth (In The Womb), Known As DES Sons 
This section addresses questions about increased health risks for DES Sons, including information on 
• non-cancerous epididymal cysts (growths on the testicles); 
• other genital abnormalities; 
• infertility; 
• ongoing follow-up studies; 
• steps for obtaining screenings and tests; and 
• what to tell your siblings about DES. 
My mother was prescribed DES while pregnant with me.  Am I at an increased risk for any 
health problems? 
Only a few studies have focused on health problems experienced by men exposed to DES before 
birth (in the womb), known as DES Sons.  The research has focused on the following health con­
cerns among DES Sons. 
• Non-Cancerous Epididymal Cysts 
The most consistent research finding for DES Sons indicates that they have an increased risk 
for non-cancerous epididymal cysts, which are growths on the testicles (Bibbo, 1977; Gill, 
1979; Conley, 1983; Niculescu, 1985; Wilcox, 1995).  In one study, 21% of DES Sons had 
non-cancerous epididymal cysts compared with 5% of unexposed men (Gill, 1979).  
• Other Genital Abnormalities 
Whether DES increases the risk for other genital abnormalities in men remains unclear.  A few 
studies have reported that DES Sons experience a greater likelihood of being born with unde­
scended testicles (cryptorchidism), a misplaced opening of the penis (hypospadias), or a smaller 
than normal penis (microphallus).  These studies estimated that 15%–32% of DES Sons expe­
rience one or more of these structural differences compared with 5%–8% of unexposed men 
(Gill, 1979; Wilcox, 1995).  Other studies, however, have not identified an increased risk of 
structural differences (Leary, 1984; Vessey, 1983).  Because findings have been inconsistent, 
researchers cannot say with certainty that DES causes these types of genital abnormalities in 
DES-exposed men. 
• Infertility 
DES Sons are not at an increased risk for infertility. Some DES Sons have been concerned 
that DES exposure might be linked to infertility.  Although one study found a lower sperm 
count in men exposed to DES compared with unexposed men (Gill, 1979), a 40-year follow-
up study of DES Sons found no increased risk of infertility among men exposed to DES 
before birth (Wilcox, 1995). 
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Are there any ongoing follow-up studies of DES Sons? 
The National Cancer Institute’s DES Combined Cohort Study began in 1992.  This study follows 
men and women exposed to DES before birth (in the womb), known as DES Sons and Daughters, 
to monitor their health patterns compared with the general population.  These cohort studies will 
continue to follow DES Sons regarding a range of health issues (such as cancer, heart disease, and 
autoimmune disease). 
Cohort studies are designed to follow the same group of people over long periods of time.  This 
means that new participants cannot be added to the study.  To learn more about cohort studies, 
refer to the section of CDC’s DES Update titled WHAT WE KNOW ABOUT DES: 
Understanding DES Research. 
What steps should I take with my health care provider in terms of special screenings or tests 
based on my DES exposure? 
Although no special screenings or tests are necessary for DES Sons, for more information about 
how to work with your health care provider, refer to the section of CDC’s DES Update titled 
WHAT YOU CAN DO ABOUT DES: Working with Your Health Care Provider. 
My younger brothers/sisters are worried that they were exposed to DES, even though my mom 
was only prescribed DES when she was pregnant with me. What can I tell them? 
Only children who were in the womb at the time their mother was prescribed DES are considered 
to have been exposed to DES.  
To learn more about the increased health risks for DES Sons, refer to the sections of CDC’s DES 
Update titled WHAT WE ARE LEARNING ABOUT DES: Recent DES Research and ADDI­
TIONAL DES RESOURCES: DES Bibliography. 
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Overview 
Researchers have been studying DES and its health effects for many years.  However, sometimes the 
data and results are difficult for non-researchers to understand.  It may also be difficult for people 
to figure out how research can be applied to their own health. 
This section of CDC’s DES Update will help you understand and use research about DES and 
includes the following information: 
• Understanding Scientific Research – Tips for interpreting and understanding scientific 
research. 
• Deciding Whether a Source is Reliable – Criteria for assessing whether a source is providing 
accurate and reliable information. 
• Role of Laboratory Animal Studies – A basis for learning about human health risks from 
laboratory animal studies. 
• Role of DES Cohort Studies – An explanation for understanding how studies of the DES 
cohorts (groups of DES-exposed persons who are included in follow-up research on DES-
related health effects) fit into the DES research picture. 
UNDERSTANDING DES RESEARCH 
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Statistical significance is expressed in scientific journals by a probability value (p-value).  P-values 
are calculated using a statistical formula that includes the number of people and health effects being 
studied and is designed to answer the question, “Could a group of this many people, who all expe­
rienced a common exposure, have had this health problem in common by chance alone?”  A find­
ing is considered statistically significant if there is less than a 5% probability (p=.05 or less) that the 
findings resulted from chance.  Conversely, if there is greater than a 5% probability (p=.06 or 
greater) that a finding resulted from chance, the finding is not statistically significant.  
How do I interpret statistics in research about DES-related health risks? 
Understanding research about DES-related health risks without knowing how to interpret statistics 
can be difficult. The following table offers some examples of how scientific studies present risk 
information. 
Different Ways that 








Type of Risk 
In the general population, a woman’s life­
time risk of developing breast cancer is 
about one in eight. That means that, over 
a lifetime, in a group of eight women, one 
of those women would be expected to be 
diagnosed with breast cancer. 
One in eight 1:8 .13 or 13% Absolute risk* 
For women prescribed DES while preg­
nant, lifetime risk of developing breast 
cancer is one in six. That means that, 
over a lifetime, in a group of six women 
exposed to DES during pregnancy, one of 
those women would be expected to be 
diagnosed with breast cancer. 
One in six 1:6 .16 or 16% Absolute risk 
For women prescribed DES while pregnant, 
the risk for breast cancer is approximately 
30% higher than for women who were not 
exposed to DES during pregnancy. 
Approximately 30% From 1:8 to 1:6 .30 or 30% Relative risk** 
Source of risk information in this chart: Titus-Ernstoff L, et al. Long term cancer risk in women given diethylstilbestrol (DES) during pregnancy. Br J Cancer 2001;84:126-33. 
* The absolute risk is a number that represents the probability that an individual with a special risk factor (such as exposure to DES) 
will experience a health effect (e.g., breast cancer). 
** Relative risk is the comparison of disease rates (e.g., breast cancer) between persons with higher risks and those in the general pop­
ulation (who have no special exposure). 
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What is a “cohort” study?  
A “cohort” is a group of people who share common characteristics or experiences.  By compiling 
and summarizing data from a cohort, scientists can observe whether disease conditions develop at 
higher rates in a cohort group than they would expect in the general population. 
In this case, a DES cohort is a group of people who were exposed to DES.  Scientists have been fol­
lowing DES cohorts for several years, to evaluate their medical conditions and disease rates. 
Researchers are trying to determine whether DES-exposed women and men are at an increased risk 
for certain health problems compared with the general population.  For instance, one cohort study 
revealed that one in six women prescribed DES while pregnant can be expected to develop breast 
cancer in her lifetime, compared with an expected rate of one in eight women in the general popu­
lation (Titus-Ernstoff, 2001). 
Deciding Whether a Source is Reliable 
Many sources of information about DES are available.  Knowing if the information can be trusted 
can be difficult. The following are some criteria to help you consider the reliability of a source. 
Where was the research published? 
Health care providers trust and use research published in credible, peer-reviewed scientific journals 
because experts have reviewed studies published in these journals to make sure they are of high 
quality.  Some examples of credible, peer-reviewed journals are JAMA, the Journal of the National 
Cancer Institute, the New England Journal of Medicine, and Science. If you have any questions about 
whether a journal is peer-reviewed, ask a librarian or your health care provider. 
How does the new information fit with what is already known? 
Each research study contributes to an existing body of knowledge.  Usually, more weight can be 
given to study findings that support and build on the findings of other research.  If the findings of 
one study contradict the findings of previous studies, months or several years may pass before more 
information becomes available to support the contradictory study.  In other words, one study alone 
is never enough to make a case – it simply gives direction about what new research is needed. 
How does funding influence research? 
Objectivity, the ability to report study results without personal bias, is an important consideration. 
The source of funding for a research project may bias the reporting of results.  The funding source 
is usually included in the journal article.  When reading an article from a funded research project, 
you must consider whether the funders of this research had anything to gain by the results.  When 
research is paid for by a source that does not have an interest in the results, funders’ expectations or 
preferences were less likely to have influenced the results. 
Can I trust information from television, magazines, or brochures? 
Many health reports in the media are based on articles published in peer-reviewed journals; howev­
er, some reports are not.  When you see a report on television, in a magazine, or in a brochure, you 
must consider where this information came from, who provided the information, whether the 
source is credible, who did the study, and whether it is consistent with other research.  If you are 
unsure, ask your health care provider. 
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Following is a list and brief description of the DES Cohort Studies. 
• Diethylstilbestrol Adenosis Project (DESAD) – The DESAD began in 1974 at Baylor 

College of Medicine, Gundersen Clinic, Massachusetts General Hospital, the Mayo Clinic, and 

the University of Southern California.  The DESAD, the largest DES cohort, included 4,014 

DES Daughters and 1,033 unexposed women.  Exposed women had documented evidence of 

DES exposure through review of prenatal records or by physician referral.  The DESAD was 

assembled to conduct studies to determine if DES Daughters were at an increased risk for 

health problems related associated with their exposure to DES (Labarthe, 1978). 

• DES Mothers Study – The DES Mothers Study began in 1980.  The participant group 

(cohort) included approximately 3,000 women exposed to DES while pregnant and 3,000 

unexposed women. These participants had delivered babies during 1940–1960 at Boston 

Lying-In Hospital, the Mayo Clinic, Dartmouth Medical School, and a private practice in 

Portland, Maine.  Exposure status was determined through review of medical records.  The 

cohort was created to determine if women exposed to DES during pregnancy were at increased 

risk for cancer (Greenberg, 1984). 

• Mayo Clinic Sons Study – The Sons Study included approximately 800 men exposed to DES 

before birth (in the womb) and 600 unexposed men.  This cohort was identified by review of 

medical records of women who gave birth at Mayo Clinic hospitals (Leary, 1984). 

• Connecticut Mothers Study – The participants included women who delivered babies during 

1946–1965 at medical offices in Fairfield and New Haven Counties, Connecticut.  The 

participants included 1,706 DES-exposed mothers and 1,405 unexposed mothers.  The 

participants are now included in the DES Combined Cohort Studies (Hadjimichael, 1984). 

• Dieckmann Cohort – Participants in the group, assembled in 1974 to study DES-related 

health risks, included approximately 800 women exposed to DES while pregnant and 800 

unexposed mothers; approximately 400 women exposed to DES before birth (in the womb) 

and 400 women in a control group; and approximately 400 men exposed to DES before birth 

and 400 unexposed men. The 1974 group comprised the second Dieckmann cohort; the first 

included mothers who were participants in a study at the University of Chicago in the early 

1950s. Results based on the initial study indicated that DES was not effective in preventing 

miscarriages (Dieckmann, 1953). 

• British Research Medical Council (BRMC) Study – Participants included pregnant diabetic 

women enrolled in clinical trial and DES Daughters and DES Sons identified through follow-





• British Randomized Trial – A group assembled to study DES-related health effects. 

Participants included women exposed to DES during pregnancy and men and women exposed 

before birth (in the womb).  The DES-exposed group included 379 mothers, 144 daughters, 

and 177 sons. A control group of unexposed included 371 mothers, 170 daughters, and 163 

sons (Guisti, 1995). 
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• Registry for Research on Hormonal Transplacental Carcinogenesis – The Registry was 
established at Massachusetts General Hospital in 1971 to track the incidence of clear cell 
adenocarcinoma (CCA) of the vagina or cervix.  The registry originally numbered 21 cases; 
however, by 2002, approximately 750 cases had been recorded at the registry.  Most of the 
information on treatment outcome and recurrence rates of CCA has come from the study of 
patients in the registry. The registry is now located at the University of Chicago (Department 
of Obstetrics and Gynecology, The University of Chicago, 5841 South Maryland Avenue, Mail 
Code 2050, Chicago, IL, 60637. Phone: 773-702-6671. Fax: 773-702-5161) (Herbst, 1972). 
What kinds of research are still going on? 
Researchers continue to monitor the health status of 15,000 members of the combined cohort 
study.  Many of the health problems being monitored are health problems that may be influenced 
by exposure to DES before birth (in the womb).  These health problems include breast cancer in 
women, testicular cancer in men, and the potential interaction of hormone replacement therapy 
with DES exposure.  
Researchers also are monitoring rates of health problems that appear to have no relationship to 
DES exposure (such as heart disease and diabetes).  Scientists have no hypothetical or other reason 
to believe there is any link between DES and these diseases.  These studies are being done to evalu­
ate the overall health of DES-exposed persons. 
Why don’t we have final answers about DES health risks? 
The health risks associated with DES exposure change over a person’s lifetime. Consequently, 
research is ongoing to learn how health risks change as DES-exposed persons age. 
For instance, DES Daughters who are still in their 30s may not have yet faced their risk for infertil­
ity, ectopic pregnancy, or other pregnancy complications.  Older DES Daughters and their mothers 
could be just reaching the stage of life where they must make an informed decision about estrogen 
replacement therapy.  Age of DES-exposed persons is particularly relevant when thinking about 
DES exposure and cancer risk.  Most cancer diagnoses do not begin to emerge until people are well 
into their fifth decade of life. Men and women who were exposed to DES before birth (in the 
womb) are just beginning to reach that age.  Only continued research will show whether people 
who were exposed to DES before birth are at an increased risk for breast cancer, prostate cancer, 
and other diseases. 
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Between the time that diethylstilbestrol (DES) was first manufactured in 1938 and the discovery of 
related health problems in 1971, approximately 5–10 million pregnant women and their children 
were exposed to the drug.  In 1971, the Food and Drug Administration (FDA) issued a warning to 
physicians advising them not to prescribe DES to pregnant women.  The warning was based on a 
discovery the same year that exposure to DES before birth (in the womb) increased the risk of clear 
cell adenocarcinoma (CCA) of the vagina (Herbst, 1971) and cervix (Noller, 1972).  Since the time 
that DES was linked to CCA, researchers have been monitoring the health problems of women 
prescribed DES during pregnancy and their children exposed to DES before birth (in the womb). 
For more information on the confirmed health risks, refer to the section of CDC’s DES Update 
titled WHAT WE KNOW ABOUT DES: Known DES Health Effects. 
Researchers are currently working to learn more about DES.  It is possible that they will learn about 
new health risks as individuals who were exposed to DES grow older.  Health risks that are currently 
being investigated and related concerns that may not be confirmed by research are discussed in this 
section. Staying informed about DES is important, giving you the knowledge to ask your health 
care provider appropriate questions to protect your health and the health of your family. 
This section of CDC’s DES Update includes the following information. 
• Recent DES Research – A review of current DES research. 
• Related Concerns – A discussion of potential, but unconfirmed, health risks and other related 
health issues. 
• DES Teleconferences – A series of conversations with DES researchers and clinical experts. 
To learn more about how DES research is conducted, refer to the section of CDC’s DES Update 
titled WHAT WE KNOW ABOUT DES: Understanding DES Research. 
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Cancer Risk in Women Exposed to Diethylstilbestrol In Utero (Hatch et al., 1998) 
In this study, the researchers wanted to learn whether women exposed to DES before birth (in the 
womb), known as DES Daughters, were more likely to develop cancer than unexposed women. 
Cancer rates of DES Daughters were also compared with cancer rates among women in the general 
population whose DES exposure status was unknown.  At the time of this study, researchers accept­
ed that DES exposure before birth increased a woman’s risk of developing clear cell adenocarcinoma 
(CCA) of the vagina and cervix.  However, researchers were not certain whether the risk for other 
types of cancer also increased.  
Over a 16-year period, the researchers compared the medical histories of 3,650 DES Daughters 
with those of 1,202 unexposed women. The researchers then compared cancer rates from the two 
study groups to cancer rates for women in the general population whose DES exposure status was 
not known.  
The researchers found that for DES Daughters, the rate for all types of cancer (other than CCA) 
was similar to the rates for unexposed women and women in the general population. In addition, 
DES Daughters were 40 times more likely than women in the general population to develop CCA.  
Although this study was one of the largest of its kind, the study had some limitations. For exam­
ple, the average age of DES Daughters who participated was 24 at the start of the study and 38 at 
last follow-up.  The researchers suggested continued study of these DES Daughters for any 
increased cancer risks during menopausal years. 
Another limitation of this study concerned breast cancer.  Many studies have demonstrated that 
women exposed to estrogen in high doses or over a long period of time have an increased risk for 
breast cancer.  However, breast cancer is most likely to occur in older women.  Thus, the women in 
this study will have to be monitored over the next several decades to determine whether DES 
Daughters develop breast cancer at higher rates than do unexposed women. 
Citation: Hatch EE, Palmer JR, Titus-Ernstoff L, Noller KL, Kaufman RH, et al. Cancer risk in women exposed to 
diethylstilbestrol in utero. JAMA 1998;280:630-4. 
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Cancer Risk in Men Exposed In Utero to Diethylstilbestrol (Strohsnitter et al., 2001) 
Since the discovery of an increased cancer risk among DES Daughters in 1971, some researchers 
have investigated whether men exposed to DES before birth (in the womb), known as DES Sons, 
also have an increased risk of cancer.  Researchers hypothesized that DES exposure could increase 
the risk for testicular cancer because prenatal exposure to abnormal levels of other types of estrogen 
have been associated with this cancer.  Previous studies of the relationship between exposure to 
DES before birth and an increased risk of testicular cancer were inconclusive.  Some studies showed 
an increased rate of testicular cancer for DES Sons compared with unexposed men, and other stud­
ies indicated no differences. 
The authors of this study conducted a follow-up study comparing the cancer rates of DES Sons 
with the cancer rates of unexposed men. A total of 2,759 men participated in the study, including 
1,365 DES-exposed men and 1,394 unexposed men. The study included a review of death certifi­
cates for 48 men who died during 1978–1994 from any type of cancer.  Researchers also reviewed 
the men’s medical histories for 1978–1994, including any cancer risk factors (such as smoking or a 
previous history of cancer).  The researchers compared the number of cancer cases in the DES-
exposed men with the number of cancer cases in unexposed men. These rates also were compared 
with cancer rates for men in the general population (whose DES exposure status was not known). 
The researchers found that the overall rate of cancer in DES Sons was not higher than the rate of 
cancer in the general population. However, the researchers did find that slightly more cases of tes­
ticular cancer occurred in DES-exposed men than in unexposed men, or than would be expected in 
the general population. Seven DES Sons were diagnosed with testicular cancer at ages 23–41, com­
pared with two unexposed men ages 28 and 40.  
Even with the higher rates of testicular cancer among DES Sons, the study did not prove an associ­
ation between exposure to DES before birth and testicular cancer.  The number of DES Sons diag­
nosed with testicular cancer was not large enough to prove an association.  In other words, the 
higher rate of testicular cancer among DES Sons could have resulted from chance rather than expo­
sure to DES.  In addition, researchers did not know the amount of DES taken by mothers of the 
DES Sons in the study, or the timing of DES prescriptions during pregnancy.  Dosage and timing 
could result in different cancer risks. 
Citation: Strohsnitter WC, Noller KL, Hoover RN, Robboy SJ, Palmer JR, et al.  Cancer risk in men exposed in utero 
to diethylstilbestrol. Journal of the Natl Cancer Inst 2001;93:545-51. 
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Long-Term Cancer Risk in Women Given Diethylstilbestrol (DES) During Pregnancy 
(Titus-Ernstoff et al., 2001) 
Since the late 1970s, research has assessed the health risks for women prescribed DES while preg­
nant. Several studies conducted in the 1970s and 1980s demonstrated a modestly increased risk for 
breast cancer among DES-exposed women.  However, not all findings were statistically significant, 
meaning that the higher rate of breast cancer among DES-exposed women could have resulted 
from chance rather than DES exposure.  Other studies suggested that higher risks of endometrial 
(uterine) and ovarian cancer occurred in women prescribed DES while pregnant.  Researchers were 
concerned about DES exposure and the increased risk for all three types of cancer because cancer of 
the breast, uterus, and cervix are all affected by exposure to hormones. 
The researchers designed this study as a follow-up to evaluate long-term cancer risks, especially 
breast cancer, for women prescribed DES while pregnant.  The medical records of women who par­
ticipated in other research on DES exposure during pregnancy were studied.  Information was 
gathered from 2,019 women prescribed DES while pregnant and 1,978 women who were not pre­
scribed DES while pregnant.  In addition, researchers studied the medical records of women from 
earlier studies who had died and determined how many of those deaths were the result of cancer. 
Using both sets of medical records, researchers were able to examine the medical records of 3,844 
DES-exposed women and 3,716 unexposed women. With this information, the researchers com­
pared the cancer rates of DES-exposed women to the cancer rates of unexposed women; they also 
compared the rates of cancer for these women in the study to the rates of cancer in the general pop­
ulation of women whose DES exposure status was not known.  
The researchers found that women prescribed DES while pregnant had a 20%–30% higher risk of 
developing breast cancer than unexposed women and women in the general population.  The 
researchers found no increased risk for any other cancers, including endometrial or ovarian cancer.  
The findings of this study indicated that approximately 16% of women who were prescribed DES 
while pregnant developed breast cancer.  In comparison, approximately 13% of women who were 
not prescribed DES while pregnant developed breast cancer.  In other words, one in six women 
exposed to DES while pregnant are likely to develop breast cancer, compared with one in eight 
women not exposed to DES while pregnant.  The increased risk of breast cancer did not appear to 
be interactive with other risk factors (such as use of hormone replacement therapy (HRT), use of 
birth control bills, or family history of breast cancer).  That means that DES exposure, in addition 
to HRT or family history, did not increase the risk of breast cancer higher than that caused by DES 
exposure alone. 
Citation: Titus-Ernstoff L, Hatch EE, Hoover RN, Palmer JR, Greenberg ER, et al. Long-term cancer risk in women 
given diethylstilbestrol (DES) during pregnancy. Br J Cancer 2001;84:125-33. 
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Infertility Among Women Exposed Prenatally to Diethylstilbestrol (Palmer et al., 2001) 
For several decades, researchers have tried to determine whether exposure to DES before birth (in 
the womb) affects a woman’s ability to become pregnant.  Two earlier studies provided conflicting 
results that may have occurred because the women were in their early childbearing years when the 
studies were conducted and because their fertility histories were incomplete.  In this study, the aver­
age age was 42; so these women had had many more reproductive years than women included in 
the two earlier studies. 
This study compared the reproductive history of 1,753 DES Daughters with the reproductive his­
tory of 1,050 women not exposed to DES.  The researchers found that compared with unexposed 
women, a greater number of DES Daughters had never become pregnant.  Similarly, a greater num­
ber of DES Daughters, compared with unexposed women, tried for a year or more to become preg­
nant without success. In addition, researchers found that the timing of DES exposure in the womb 
(the trimester(s) during which exposure to DES took place) had some effect on infertility rates.  
Specifically, 24% of DES Daughters had never become pregnant compared with 18% of unexposed 
women. Most DES Daughters who never became pregnant had been exposed to DES during the 
first 9 weeks in the womb.  This finding supports earlier research, which found that structural 
abnormalities that affect fertility (such as endometriosis, abnormalities of the fallopian tubes, and 
inadequate production of cervical mucus) were more common among women whose DES exposure 
occurred during their mothers’ first trimester of pregnancy.  
Despite problems with becoming pregnant, 76% of DES Daughters eventually became pregnant 
compared with 82% of unexposed women.  
Citation: Palmer JR, Hatch EE, Rao RS, Kaufman RH, Herbst AL, et al. Infertility among women exposed prenatally 
to diethylstilbestrol.  Am J Epidemiol 2001;154:316-21. 
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RECENT DES RESEARCH 
Hypospadias in Sons of Women Exposed to Diethylstilbestrol In Utero: A Cohort Study 
(Klip et al., 2002) 
Although laboratory animal studies have reported third-generation (offspring of DES Daughters 
and Sons) health effects of DES exposure, little is known about human health effects in the chil­
dren of the women exposed to DES before birth.  The goal of this study was to examine the risk of 
hypospadias (abnormality of the penis) in the sons of women exposed to DES before birth.  
This Dutch cohort study consisted of a questionnaire of 16,284 women with diagnosed fertility 
problems.  The researchers compared the prevalence of the rate of hypospadias between the sons of 
mothers who had been exposed to DES before birth with sons whose mothers had not been 
exposed to DES. The mothers of 205 sons reported DES exposure, and four of these sons had con­
firmed hypospadias; eight sons of the remaining 8,729 sons in the study had hypospadias.  Risk of 
hypospadias was not affected by maternal age, fertility treatment, or use of assisted reproductive 
techniques. 
Results suggested that although absolute risk was small, the third-generation health effects of DES 
exposure warrant additional studies. 
Citation: Klip H, Verloop J, van Gool JD, Koster META, Burger CW, van Leeuwen FE. Hypospadias in sons of 
women exposed to diethylstilbestrol in utero: a cohort study.  Lancet 2002; 359:1102-7. 




RECENT DES RESEARCH 
Risk of Breast Cancer in Women Exposed to Diethylstilbestrol In Utero: Preliminary Results 
(United States). (Palmer et al., 2002) 
In this prospective follow-up study, researchers wanted to learn whether women exposed to DES 
before birth (in the womb), known as DES Daughters, were more likely to develop breast cancer 
than unexposed women. Information on reproductive factors, behavioral risk factors and health 
problems, including breast cancer, was gathered in 1994 from 4,821 DES Daughters and 2,095 
unexposed women. Three years later, 3,916 DES Daughters and 1,746 unexposed women com­
pleted a short follow-up questionnaire that asked about new occurrences of disease.  The researchers 
confirmed results of the surveys by checking medical reports or death certificates.  The data revealed 
that 43 cases of breast cancer occurred among DES Daughters and 15 cases occurred among the 
unexposed. 
Findings of the study are not definitive, but suggest that exposure to DES before birth (in the 
womb) may be associated with an increased risk of breast cancer.  The risk of breast cancer for DES 
Daughters as a whole group is slightly higher than estimated in earlier studies (Hatch, 1998), but is 
not a statistically significant increase (that means the higher incidence of breast cancer could be the 
result of chance, rather than being associated with exposure to DES).  
The study findings were different, depending upon the age of the study participants. 
DES Daughters under age 40 did not have a higher risk of breast cancer than unexposed women 
under 40. However, DES Daughters who were over 40 years old who participated in the study 
were 21/2 times more likely to experience breast cancer than were unexposed women over age 40. 
The increased risk was statistically significant (not due to chance, but increased risk was more likely 
to be related to association with DES exposure). 
It is important to note that the findings from this study are viewed as preliminary due to some lim­
itations of the research.  Although participants had been followed for an average of 19 years, the 
median age of the study group in 1997 was 43 years, an age when breast cancer incidence is still 
relatively low in the general population.  Continued investigation as the group of DES Daughters 
grow older is necessary to have enough data to determine if DES exposure is indeed linked to an 
increased risk of breast cancer among women exposed before birth (in the womb). 
In addition, while the DES Daughters and unexposed women in the study were similar in most 
respects, they differed in some important areas.  DES Daughters in the study were more likely to be 
older when they gave birth to their first child or to have had fewer or no children than were unex­
posed women. Both these characteristics have been associated with increased incidence of breast 
cancer and raise questions about whether DES exposure or other characteristics might be responsi­
ble for increased risks. 
Citation: Palmer JR, Hatch EE, Rosenberg CL, Hartge P, Kaufman RH, Titus-Ernstoff L, et al.  Risk of breast cancer 
in women exposed to diethylstilbestrol in utero: preliminary results (United States). Cancer Causes Control 
2002;13:753-8. 
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RELATED CONCERNS 
Potential Health Risks: Women Exposed To DES Before Birth (In The Womb), Known As DES 
Daughters 
Are DES Daughters at an increased risk for cancer or other health problems? 
Ongoing research has confirmed health risks for DES Daughters including increased incidence of 
clear cell adenocarcinoma (CCA), structural abnormalities in the reproductive organs, infertility, 
and pregnancy complications.  (To read more about confirmed health risks, refer to the section of 
CDC’s DES Update titled KNOWN DES HEALTH EFFECTS: Women Exposed to DES Before 
Birth (In the Womb), Known as DES Daughters.) However, recent research findings raise additional 
concerns about health problems associated with DES exposure for women exposed before birth. 
Although research has not provided definitive answers for these questions, DES Daughters and their 
health care providers should be aware of these emerging issues and remain up-to-date on current 
research in these areas. 
Age of Diagnosis for CCA in DES Daughters 
Early studies of this health risk suggested that CCA was primarily a risk for DES Daughters in their 
teens and 20s. More recent information from the CCA registry at the University of Chicago shows 
that DES Daughters in their 30s and 40s have been diagnosed with CCA (Hatch, 1998).  No one 
knows how common CCA may be as the majority of DES Daughters enter their 50s and 60s.  As a 
result, CCA is now considered a lifetime risk for DES Daughters. 
Cervical Intraepithelial Neoplasia (CIN) 
Scientists are also investigating if DES Daughters have an increased risk of a condition called cervical 
intraepithelial neoplasia. Cervical intraepithelial neoplasia (CIN) is a general term for the growth of 
abnormal cells on the surface of the cervix.  One recent study found that DES Daughters are twice as 
likely to experience CIN as unexposed women (Hatch, 2001).  An earlier study found that DES 
Daughters are two to four times more likely than unexposed women to have abnormal cells changes 
on the cervix or to experience cervical carcinoma in situ (CIS).  CIS involves only the cells in which 
the cancer begins, but does not spread to nearby tissues (Robboy, 1984).  More recently, researchers 
analyzed experiences of women from the Netherlands DES Information Center.  DES Daughters 
registered at the Information Center reported three times the incidence of cervical cancer as did 
unexposed women (Verloop, 2000).   
Breast Cancer 
Exposure to estrogen before birth has been linked to increased risk for breast cancer 
(Trichopoulous, 1990; Potischman, 1999).  As a result, concerns have been raised about whether 
DES Daughters have an increased risk of breast cancer.  
Until recently the majority of DES Daughters were too young to determine whether DES exposure 
increased their risk of breast cancer.  However, a recent study provides initial results linking expo­
sure to DES before birth with increased rates of breast cancer (Palmer, 2002).  The study found 
that among study participants, DES Daughters were more likely to experience breast cancer than 
were unexposed women.  DES Daughters had a relative risk of 1.4 (40% higher incidence of breast 
cancer). However, the finding was not statistically significant, which means that the increased rate 
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of breast cancer could have been the result of chance.  The study did find that, in study participants 
over 40, DES Daughters were two-and-a-half times more likely than unexposed women to be diag­
nosed with breast cancer.  The results for women over 40 were statistically significant (not likely to 
be due to chance). DES Daughters under 40 years of age did not experience an increased risk of 
breast cancer.  The findings from this study are considered preliminary until confirmed and refined 
by other research.  However, DES Daughters and their health care providers should be aware of this 
research and follow breast cancer screening guidelines recommended by the American Cancer 
Society (ACS) or the National Cancer Institute (NCI).  Guidelines for breast cancer screening can 
be found at the ACS Web site (www.cancer.org) or at the NCI Web site (www.cancer.gov). 
Research on additional health concerns is ongoing because as DES Daughters experience 
menopause, a time during which certain conditions (such as osteoporosis, breast cancer, and cervi­
cal cancer) become more common in the population, continued monitoring is necessary. While 
research continues, you should protect your health by staying informed and talking with a health 
care provider about screenings for age-related cancers.  
For more information about protecting your health, refer to the section of CDC’s DES Update 
titled WHAT YOU CAN DO ABOUT DES: Protecting Your Health and the Health of Your 
Family. 
Considering that I was exposed to DES before birth (in the womb), is it all right for me to take 
birth control pills? 
Some DES Daughters wonder whether they should use birth control pills.  The decision about 
birth control methods is a very personal one.  Women should talk with their health care providers 
about the best method for each woman based on medical conditions and health history.  Research 
can also help women make informed medical decisions. Research has not found DES Daughters to 
be at risk for any cancers except clear cell cancer of the vagina and cervix (Hatch, 1998).  The 
largest study of DES Daughters to date found that use of birth control pills by DES Daughters did 
not increase the risk for breast cancer or any other type of cancer (Hatch, 1998).  The recently pub­
lished Women’s Contraceptive and Reproductive Experience Study found that use of birth control 
pills did not increase women’s risk of breast cancer (Marchbanks, 2002).  The study included more 
than 9,000 women, but did not include information about their DES exposure status. 
Should DES Daughters consider hormone replacement therapy (HRT)? 
Research on DES Daughters and HRT has been limited because many DES Daughters were born 
in the 1950s and 1960s and have yet to reach menopause—the time when replacing estrogen is 
typically considered.  Studies are ongoing and researchers continue to evaluate any possible links 
between exposure to DES before birth (in the womb) and risks associated with HRT. The decision 
to take HRT is a personal one and should be made in consultation with your health care provider.  
For more information on hormone replacement therapy (HRT), refer to the following sources. 
• CDC Information About Hormone Replacement Therapy Web site
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RELATED CONCERNS 
Potential Health Risks: Third Generation (the Offspring of DES Daughters and Sons) 
Do the children of DES Daughters and Sons have any health risks? 
Third-generation children (the offspring of DES Daughters and Sons) are just beginning to reach 
the age when relevant health problems (such as reproductive tract problems), can be studied. 
A study of the health risks for the daughters of DES daughters, or third-generation daughters, was 
published in 2002. The researchers compared findings of pelvic examinations of 28 daughters with 
findings noted in their mothers (DES Daughters).  Even though abnormalities were present in more 
than 60% of DES Daughters, no abnormalities were found in their daughters (Kaufman, 2002). 
Sons of DES Daughters are being studied at the Netherlands Cancer Institute.  Early research 
reported that hypospadias, misplaced opening of the penis, occurred 20 times more frequently 
among sons of DES Daughters (Klip, 2002).  
What is known about a third-generation health risks from laboratory animal studies? 
In laboratory animal studies of elderly third-generation DES-exposed, female mice, an increased 
risk of uterine cancers, benign ovarian tumors, and lymphomas was found.  Elderly third-genera­
tion DES-exposed male mice were at an increased risk of certain reproductive tract tumors.  Both 
the female and male mice studied were the offspring of female mice exposed to DES before birth 
(in the womb). While DES research about third-generation health risks continues, you should pro­
tect your health by staying informed and talking with a health care provider about your concerns. 
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RELATED CONCERNS 
Potential Health Risks: General Questions
 

What is known about DES and autoimmune diseases? 
Although laboratory animal studies of mice exposed to DES before birth (in the womb) suggested 
an increased risk of autoimmune disease in female mice, studies among humans have reported 
mixed results.  One study indicated that autoimmune diseases occurred more often in women 
exposed to DES before birth (in the womb), known as DES Daughters, than in the general popula­
tion. However, no one autoimmune disease (such as rheumatoid arthritis or lupus) occurred more 
often than others (Noller, 1988).  Researchers will continue to explore this issue. 
What other health risks have been studied? 
No studies of humans have documented consistent findings linking DES exposure to any psycho­
logical condition or sexual dysfunction. However, some laboratory animal studies suggested links 
between exposure to estrogens before birth (in the womb) and cognitive abilities.  For more infor­
mation refer to topic “Psychology” in the section of CDC’s DES Update titled ADDITIONAL 
DES RESOURCES: DES Bibliography. 
CDC’s DES Update Toll-free 1-888-232-6789 www.cdc.gov/DES 






You can take steps to protect your health and the health of your family.  Whether you were pre­
scribed DES while pregnant or exposed to DES before birth (in the womb), the information and 
resources in this section will help you 
• work with your health care provider; 
• protect your health and the health of your family; and 
• keep a DES health information record. 
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 WORKING WITH YOUR HEALTH CARE PROVIDER 
How to Work Effectively with Your Health Care Provider 
To stay informed about DES and protect your health, you should communicate regularly with your 
health care provider (for instance, your physician, physician’s assistant, nurse, or nurse practitioner). 
Talking with your health care provider is not always easy; some patients hesitate to ask questions 
during regular office visits or check-ups because it is difficult for them to ask about complex issues 
such as DES. Others may be reluctant to contact their health care provider between office visits 
unless it is an emergency.  But your health care provider needs to know your questions and con­
cerns. Addressing your questions and concerns is the best way your health care provider can work 
with you to protect your health.  You must take the initiative and help your health care provider 
give you the most effective care – the care that is right for you.  
This section of CDC’s DES Update addresses some of the most common questions and concerns 
that patients ask about how to work with a health care provider. 
My health care provider has never talked with me about DES exposure. 
If your health care provider has not talked with you about DES exposure, you can initiate the con­
versation.  Most health care providers only have a few patients who have been exposed to DES, so 
they rarely have patients ask about the topic.  Although CDC’s DES Update is designed to give 
health care providers current information and resources for working with patients, if you do not 
mention your DES exposure, your health care provider will likely remain unaware. 
I know (or have strong reason to suspect) that I was exposed to DES.  What should I expect my 
health care provider to do? 
Once your health care provider knows or suspects you were exposed to DES, certain screenings to 
check for DES health effects may be recommended.  You and your health care provider can work 
together to set up a screening schedule that may minimize your risk of health problems.  For a list 
of recommended screenings, see the section of CDC’s DES Update titled WHAT YOU CAN DO 
ABOUT DES: Protecting Your Health and the Health of Your Family. 
Are there materials I can take to my health care provider to help us talk about DES? 
The following are some DES resources that you can take to your health care provider.  
• CDC’s DES Update summary card titled WHAT YOU CAN DO ABOUT DES: CDC’S 
DES Update in Brief. 
• Downloadable materials from CDC’s DES Update Web site at www.cdc.gov/DES. 
• Recent DES research summarized in the section of CDC’s DES Update titled WHAT WE 
ARE LEARNING ABOUT DES: Recent DES Research. 
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What can I do if I want or need to change health care providers? 
If you do not have a health care provider, or if your health care provider does not meet your needs, 
ask for recommendations from family, friends, or other health care providers.  Be sure to check with 
your health care plan about any network or referral requirements.  
You can also contact the consumer advocacy group, DES Action USA.  DES Action has compiled a 
National Physician Referral List that includes physicians who have experience working with DES-
exposed patients. This referral list can be obtained free of charge.  Other health care providers in 
your area also may know about DES, but this referral list is a good place to start.  Contact DES 
Action by telephone (1-800-DES-9288) or by e-mail (desaction@earthlink.net). 
My gynecologist knows about my DES exposure.  Do I need to tell my other health care 
providers? 
Yes.  Your DES exposure is a part of your health history, and all of your health care providers 
should know about it.  The more your health care providers know about your health history, the 
more you can work together to protect your health. 
In addition, you should keep copies of your medical records, especially if you see more than one 
physician. To help you keep track of your DES health history, including DES-related health prob­
lems, refer to the section of CDC’s DES Update titled WHAT YOU CAN DO ABOUT DES: 
DES Health Information Record. 
The American College of Obstetricians and Gynecologists is a resource for names of obstetricians, 
gynecologists, and maternal-fetal medicine specialists. Contact the Resource Center at The 
American College of Obstetricians and Gynecologists at 202-863-2518, P. O. Box 96920, 
Washington, D.C., 20090-6920, or www.acog.org. 
I am a DES Son.  Who should be aware of my DES exposure? 
DES Sons should tell their primary care provider about their DES exposure.  If you already have a 
urologist, be sure he or she is aware of your DES exposure.  If you do not have a urologist, your 
primary health care provider can refer you to one, if necessary. 
What is CDC doing to help educate health care providers? 
CDC’s DES Update is working with health care providers around the country to increase awareness 
about recent DES research and to give them current information and resources for working with 
patients. You can also help with this effort.  When you visit your health care provider, bring along 
the summary card in the section of CDC’s DES Update titled WHAT YOU CAN DO ABOUT 
DES: CDC’S DES Update in Brief. 
This card also includes a list of the resources available for health care providers.  In addition, CDC’s 
DES Update Web site (www.cdc.gov/DES) has information and resources specifically designed for 
health care providers, along with information and resources for people who were exposed to DES. 








 WORKING WITH YOUR HEALTH CARE PROVIDER 
Questions To Ask Your Health Care Provider About DES
 

The following are questions everyone should ask their health care provider. 
• Have you treated women/men who were exposed to DES? 






• Do you know about CDC’s DES Update?  






The following are questions to ask your health care provider if you were prescribed DES 
while pregnant. 
• I was prescribed DES while pregnant.  DES research shows that women like me have about a 
30% increased risk of developing breast cancer over their lifetime.  How will we plan my 
mammogram schedule and other physical exams to manage my increased risk? 
• I know that monthly breast self-exams may help protect my health.  Will you show me how to 
do a breast self-exam correctly? Does it matter what time of the month I perform breast self-
exams? 
• I was prescribed DES while pregnant with my daughter/son.  What health risks should I be 
discussing with her/him? 






The following are questions to ask your health care provider if you are a woman who was 
exposed to DES before birth (in the womb), known as a DES Daughter. 
• My mother was prescribed DES while pregnant with me.  Current DES research shows that 
DES Daughters continue to be at a higher risk for clear cell adenocarinoma (CCA) of the vagi­
na and cervix into their late 40s.  I understand I should be monitored for CCA throughout my 
lifetime. What types of screenings and exams should I receive to manage my increased risk? 
• Have you worked with any DES Daughters who were able to become pregnant? 
• Do you work with high-risk pregnancies?  If not, could you refer me to a health care provider 
who does? 
• Research shows that DES Daughters have an increased risk for structural changes of the uterus 
and cervix (such as a T-shaped uterus, cockscomb on the cervix, and hooded cervix).  Do I 
need to be examined for any of these differences?  If so, when? 
• DES research shows that DES Daughters have an increased risk of tubal pregnancies, miscar­
riages, and premature deliveries. What additional screenings or tests should we think about to 
protect my health during pregnancy? 
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• Preliminary results of DES research indicate that DES Daughters older than 40 are at higher 
risk for breast cancer.  I know that monthly breast self-exams may help protect my health. 
Will you show me how to do a breast self-exam correctly?  Does it matter what time of the 
month I perform breast self-exams? 
• What health risks does my mother have because she was prescribed DES while she was preg­
nant with me? 
• (If applicable) What health risks does my brother have because he was exposed to DES before 
birth (in the womb)? 






The following are questions to ask your health care provider if you are a man who was 
exposed to DES before birth (in the womb), known as a DES Son. 
• My mother was prescribed DES while pregnant with me.  Researchers are exploring whether 
DES exposure is linked to testicular cancer.  I know that testicular self-exams may help protect 
my health. Will you show me how to do a testicular self-exam correctly? How often should I 
do self-exams and what should I look for? 
• What health risks does my mother have because she was prescribed DES while she was preg­
nant with me? 
• (If applicable) What health risks does my sister have because she was exposed to DES before 
birth (in the womb)? 












This handout can be shared with your health care provider, family, or friends. 
Centers for Disease Control and Prevention’s 
DES UPDATE 
DES in Brief: Known Health Risks and New Resources
 

Research published 1971-2001 associates DES exposure with increased health risks for: 
WOMEN PRESCRIBED DES WHILE PREGNANT are at a modestly increased risk for 
•  Breast cancer 
WOMEN EXPOSED TO DES BEFORE BIRTH (in the womb), known as DES Daughters, are at an increased 
risk for 
• Clear cell adenocarcinoma (CCA) of the vagina and cervix 
•  Reproductive tract structural differences 
•  Pregnancy complications 
• Infertility 
n as DES Sons, are at an increased risk for MEN EXPOSED TO DES BEFORE BIRTH (in the womb), know
• Non-cancerous epididymal cysts 
CDC’s DES Update offers several free educational resources for health care providers and patients/consumers. 
To order a CD-ROM with the resources for health care providers or to order the printed resources for patients and 
consumers, visit the web site at www.cdc.gov/DES or call toll-free 1-888-232-6789. 
RESOURCES FOR HEALTH CARE PROVIDERS 
• DES Grand Rounds Presentations 
• DES Case Studies for medical, nursing, physician assistant and nurse practitioner students 
• DES Review Essays 
• CME & CEU self-study modules 
• DES Web Site 
RESOURCES FOR PATIENTS AND CONSUMERS 
•  DES Fact Sheets 
•  DES Self-Assessment 
•  Personal Health Information Record 
•  DES Web Site 
An estimated 5-10 million people were exposed to diethylstilbestrol (DES) in the United States during 1938­
1971.  DES was thought to be a safe and effective way to prevent miscarriages or premature deliveries.  However, 
later studies revealed that DES had harmful side effects.  Many people are still unaware of their exposure to DES 









This health information record can help you manage your health decisions and help you 
discuss questions about DES exposure with your health care provider. 
Each family member exposed to DES should complete a DES Health Information Record. You 
can photocopy this record or print additional copies from the CDC’s DES Update Web site 
at www.cdc.gov/DES. 
General Information 
Name ____________________________________ Social Security Number ______________________ 
Date of Birth________________________________ Blood Type ________________________________ 
Primary health care provider(s) ____________________________________________________________ 
Other Specialists ______________________________________________________________________ 
Insurance Carrier ____________________________ Policy/Plan Number ________________________ 
Group# ______________________________________________________________________________ 
Effective Date ______________________________ Phone Number ____________________________ 
Your DES Health History 
My mother was prescribed DES while she was pregnant with me. Yes ____ No____ Don’t Know ___ 
I am the son of a woman or man exposed to DES before 
birth (in the womb), also known as a DES grandchild. Yes ____ No____ Don’t Know ___ 
The following chart helps you track your health checkups. Record the date and year of your most recent 
exam. Space is provided to track future exams. 
Date/Year Date/Year Date/Year Date/Year Date/Year 








This health information record can help you manage your health decisions and help you 
discuss questions about DES exposure with your health care provider. 
Each family member exposed to DES should complete a DES Health Information Record. You 
can photocopy this record or print additional copies from the CDC’s DES Update Web site 
at www.cdc.gov/DES. 
General Information 
Name ____________________________________ Social Security Number ______________________ 
Date of Birth________________________________ Blood Type ________________________________ 
Primary health care provider(s) ____________________________________________________________ 
Obstetrician/Gynecologist________________________________________________________________ 
Other Specialists ______________________________________________________________________ 
Insurance Carrier ____________________________ Policy/Plan Number ________________________ 
Group# ______________________________________________________________________________ 
Effective Date ______________________________ Phone Number ____________________________ 
Your DES Health History 
I was prescribed DES while I was pregnant. Yes ____ No____ Don’t Know ___ 
My mother was prescribed DES while she was pregnant with me. Yes ____ No____ Don’t Know ___ 
I am the daughter of a woman or man exposed to DES before 
birth (in the womb), also known as a DES grandchild. Yes ____ No____ Don’t Know ___ 
The following chart helps you track your women’s health checkups. Record the date and year of your 
most recent gynecological exam and mammogram. Space is provided to track future exams. 
Date/Year Date/Year Date/Year Date/Year Date/Year 
Record of Gynecological Exams/Pap Tests 
Follow Up and Treatment for Abnormal Pap Tests 
Record of Mammograms 





PROTECTING YOUR HEALTH AND
THE HEALTH OF YOUR FAMILY
Women Prescribed DES While Pregnant 
Women prescribed DES while pregnant are at a modestly increased risk for breast cancer.  They 
should be screened for breast cancer with the same tests and at the same intervals as women in the 
general population. The following are action steps you can take to protect your health. 
• Have clinical breast exams and regular mammograms 
Most health care providers recommend that women 40 years of age and older have a mammo­
gram (an X-ray of the breast) every 1–2 years.  In addition, most health care providers perform 
clinical breast examinations (visual and manual examination of the breast) during routine 
physical examinations. Additional guidelines for breast cancer screening can be found at the 
National Cancer Institute (NCI) Web site (www.cancer.gov) or the American Cancer Society 
(ACS) Web site (www.cancer.org).  A description of mammography can be found at the ACS 
Web site by typing “mammography” in the search box on the home page and then clicking on 
the link to the Glossary and typing “mammography” in the cancer-related terms box. 
• Perform monthly breast self-exams 
Most health care providers recommend that you learn and practice monthly breast self-exami­
nation as a way to detect any lumps in your breasts, discharge from the nipples, or skin 
changes (such as dimpling or puckering). Instructions for breast self-examination can be 
found at the ACS Web site by typing “breast self-exam” in the search box on the home page 
and then clicking on the link “How to Perform a Breast Self-Exam.” 
• Talk with your family, especially your children, about DES 
If you have not already discussed it, you may find it difficult to tell your children they were 
exposed to DES. However, many mothers feel a sense of relief after telling their children; fam­
ily members need to know whether they were exposed to DES.  Once your children know 
about their exposure, they can get proper medical care to protect their health now and in the 
future.  
• Encourage your children to notify their health care provider about their DES exposure 
before birth (in the womb). 
• Request copies of CDC’s DES Update to share with your children.  Visit CDC’s DES 
Web site at www.cdc.gov/DES or call toll-free 1-888-232-6789. 
• Share the DES Self-Assessment 
As you talk with others about DES, they may wonder whether they were exposed to DES.  To 
assess whether they may have been exposed to DES, refer to the section of CDC’s DES Update 
titled DES SELF-ASSESSMENT: A Guide to Understanding Your Risk for DES Exposure. 
• Stay up-to-date on DES research 
Researchers continue to study DES and will learn more health information about DES expo­
sure in follow-up studies.  For more information refer to the section of CDC’s DES Update 
titled WHAT WE ARE LEARNING ABOUT DES: Recent DES Research. 
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• For more information about 
• DES exposure and related health risks, visit CDC’s DES Update Web site at 
www.cdc.gov/DES or call toll-free 1-888-232-6789. 
• Breast cancer risk for women prescribed DES while pregnant, refer to the sections of 
CDC’s DES Update titled WHAT WE ARE LEARNING ABOUT DES: Recent DES 
Research, and ADDITIONAL DES RESOURCES: DES Bibliography. 
• Breast cancer causes and prevention, visit the National Cancer Institute (NCI) Web site at 
www.cancer.gov or call the Cancer Information Service (CIS) toll-free 1-800-4-CANCER 
(1-800-422-6237). The American Cancer Society (ACS) also provides detailed informa­
tion about breast cancer screening at their Web site (www.cancer.org). 




PROTECTING YOUR HEALTH AND
THE HEALTH OF YOUR FAMILY
Women Exposed to DES Before Birth (in the Womb), known as DES Daughters 
DES Daughters are at an increased risk for clear cell adenocarcinoma (CCA) of the vagina and 
cervix, cervical intraepithelial neoplasia (CIN), reproductive tract structural differences, pregnancy 
complications, pre-term delivery, and infertility and therefore should be monitored throughout 
their lifetimes. The following are steps you can take to protect your health. 
• Schedule regular gynecological exams, including Pap test and pelvic exam 
The National Cancer Institute (NCI) published a description of appropriate pelvic examina­
tions for DES Daughters.  Pelvic examinations for DES Daughters should be performed in a 
similar manner as those performed among unexposed women. 
Pelvic examinations in DES Daughters should include 
•		careful visual examination and palpation (feeling) of the vagina and cervix with rotation 
of the speculum so that all vaginal walls can be inspected; 
•		Pap smears from the cervix and the surfaces of the upper vagina; and 
•		 iodine staining of the vagina and cervix or a colposcopy, depending on the detection of 
any abnormalities during the examination. Iodine staining allows your health care 
provider to evaluate changes in the cervix or vagina.  A colposcopy uses a device that 
works like a magnifying glass, allowing your health care provider to carefully check the 
vagina and cervix.  Your health care provider may take photographs using the colposcope 
so that any changes in your condition can be monitored during future examinations. 
• Schedule clinical breast exams and regular mammograms 
Studies have not found a statistically significantly increased risk of breast cancer among DES 
Daughters of all ages.  However, a recent study did find significantly increased risk among DES 
Daughters over age 40 (Palmer, 2002).  Since this was the first study to identify a link, research 
will continue to see if results will be repeated and to determine if DES Daughters of other ages 
also have a greater risk of breast cancer.  While research continues, DES Daughters should be 
screened for breast cancer with the same tests and at the same intervals as women in the gener­
al population. The following actions can help you protect your health. 
• Most health care providers recommend that women 40 years of age and older have a 
mammogram (an X-ray of the breast) every 1–2 years. 
• In addition, most health care providers perform a clinical breast examination (visual and 
manual examination of the breast) during routine physical examinations.  Guidelines for 
breast cancer screening can be found at the National Cancer Institute (NCI) Web site 
(www.cancer.gov) or the American Cancer Society (ACS) Web site (www.cancer.org).  
A description of mammography can be found at the ACS Web site by typing “mammogra­
phy” in the search box on the home page and then clicking on the link to the Glossary 
and typing “mammography” in the cancer-related terms box. 
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• Share the DES Self-Assessment 
As you talk with others about DES, they may wonder whether they were exposed to DES.  To 
assess whether you or others may have been exposed to DES, refer to the section of CDC’s 
DES Update titled DES SELF-ASSESSMENT: A Guide to Understanding Your Risk for DES 
Exposure. For additional copies of the DES Self-Assessment, visit CDC’s DES Update Web 
site at www.cdc.gov/DES or call toll-free 1-888-232-6789. 
• Stay up-to-date on DES research 
Researchers continue to study DES and may learn more about the health effects of DES expo­
sure.  For more information, refer to the section of CDC’s DES Update titled WHAT WE 
ARE LEARNING ABOUT DES: Recent DES Research.  
• For more information about 
• DES exposure and related health risks, visit CDC’s DES Update Web site at 
 
www.cdc.gov/DES or call toll-free 1-888-232-6789.  
 
• Health risks for DES Daughters, refer to the sections of CDC’s DES Update titled 

WHAT WE KNOW ABOUT DES: Known DES Health Effects; WHAT WE ARE 

LEARNING ABOUT DES: Recent DES Research; and ADDITIONAL DES 

RESOURCES: DES Bibliography. 





PROTECTING YOUR HEALTH AND
THE HEALTH OF YOUR FAMILY
Men Exposed to DES Before Birth (in the Womb), Known as DES Sons 
DES Sons have an increased risk of non-cancerous epididymal cysts (growths on the testicles).  The 
following are steps you can take to protect your health. 
• Perform monthly testicular self-exams 
Researchers continue to study whether DES exposure is linked with an increased risk of devel­
oping testicular cancer.  Talk with your health care provider about whether monthly testicular 
self-examinations should be a part of your regular health activities.  For information about how 
to do a testicular self-exam, refer to the American Cancer Society’s (ACS) Web site (www.can­
cer.org). 
• Talk with your family, especially your children, about DES 
Research on the health risks for the third generation (the offspring of DES Daughters and 
Sons) is just beginning.  Research will continue on these children as they age.  If future 
research identifies health risks to the third generation, informing them about their DES expo­
sure will become even more important.  To help protect your child’s health, consider taking the 
following steps. 
• Note your DES exposure on your child’s health record.  For a health information form, 
refer to the section of CDC’s DES Update titled WHAT YOU CAN DO ABOUT DES: 
DES Health Information Record.  
• Notify your child’s health care provider about your exposure to DES. 
• To learn more about the ongoing research of the third generation, refer to the section of 
CDC’s DES Update titled WHAT WE ARE LEARNING ABOUT DES: Recent DES 
Research.  
• Request copies of CDC’s DES Update to share with your children.  Visit CDC’s DES 
Update Web site at www.cdc.gov/DES or call toll-free 1-888-232-6789. 
• Share the DES Self-Assessment 
As you talk with others about DES, they may wonder whether they were exposed to DES.  To 
assess whether you or others may have been exposed to DES, refer to the section of CDC’s 
DES Update titled DES SELF-ASSESSMENT: A Guide to Understanding Your Risk for DES 
Exposure.  
For additional copies of the DES Self-Assessment, visit CDC’s DES Update Web site at 
www.cdc.gov/DES or call toll-free 1-888-232-6789. 
• Stay up-to-date on DES research  
Researchers continue to study DES and may learn more about the health effects of DES expo­
sure.  For more information refer to the section of CDC’s DES Update titled WHAT WE 
ARE LEARNING ABOUT DES: Recent DES Research. 
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• For more information about 




• Health risks for DES Sons, refer to the sections of CDC’s DES Update titled WHAT WE 
KNOW ABOUT DES: Known DES Health Effects; WHAT WE ARE LEARNING 
ABOUT DES: Recent DES Research; and ADDITIONAL DES RESOURCES: DES 
Bibliography. 
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Other resources are available to help you learn more about DES research, health risks, and support 
system. 
This section of CDC’s DES Update includes the following information. 
• Partner and Government Organizations – A list of the names and contact information for 
organizations that provide useful DES resources. 
• DES Glossary – A list of terms and definitions relevant to the topic of DES. 
• DES Bibliography – A list of published research and other sources of DES information
 

grouped by main topic.
 

• Notes – A place to record your thoughts and questions about DES. 
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PARTNER AND GOVERNMENT ORGANIZATIONS 
Overview 
Researchers continue to learn about DES.  Therefore, staying informed about DES is important for 
protecting your health.  CDC and several partner organizations can help you stay informed about 
DES and related health issues through Web sites, mailing lists, and newsletters.  This section of 
CDC’s DES Update contains a list of the names and contact information for organizations that 
provide useful DES-related resources. 
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PARTNER AND GOVERNMENT ORGANIZATIONS 
CDC’s DES Update DES Advocacy Organizations
 

CDC’s DES Update 
Phone:  (toll-free) 1-888-232-6789 
Web site:  www.cdc.gov/DES 
CDC’s DES Update was developed as a resource 
for the public and for health care providers to 
provide them with the latest, most comprehen­
sive, and accurate information about diethyl­
stilbestrol (DES).  
Resources for patients and consumers include 
• a binder of DES fact sheets; 
• DES Self-Assessment: A Guide to
 











• DES Web site. 
Resources for health care providers include 
• DES Grand Rounds presentations; 
• DES case studies; 
• DES review essays; 
• CME and CEU self-study modules; and 
• DES Web site. 
DES Action USA 
610 16th Street, Suite 301 
Oakland, CA  94612 
Phone:  (toll-free) 1-800-DES-9288 or 
510-465-4011 
Fax:  510-465-4815 
E-mail: desaction@earthlink.net 
Web site:  www.desaction.org 
DES Action USA is a national, non-profit con­
sumer organization dedicated to informing the 
public about DES and helping DES-exposed 
people. This organization offers a quarterly 
newsletter and many publications on various 
aspects of DES exposure and links DES-exposed 
people, DES researchers, and the medical 
community. 
DES Sons Network 
Michael Freilick  
104 Sleepy Hollow Place 
Cherry Hill, NJ  08003 
E-mail: msfreilick@hotmail.com 
DES Sons Network is a national network pro­
viding information and support for DES Sons 
and counseling for men with testicular cancer. 
It is affiliated with DES Action USA. 
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DES Cancer Network 
P.O. Box 220465 
Chantilly, VA  20153-0465 
Phone:  (toll-free) 1-800-DES-NET-4  
E-mail: desnetwrk@aol.com 
Web site:  www.descancer.org 
DES Cancer Network is an international advo­
cacy organization that addresses the special 
needs of women exposed to DES who have had 
clear cell adenocarcinoma (CCA) of the vagina 
and cervix.  This network provides a support 
system that gives members access to one another 
and to information about CCA. 
The DES Third Generation Network 
P.O. Box 21 





The DES Third Generation Network is an advo­
cacy network designed to collect and share infor­
mation about the health of children born to DES 
Daughters and DES Sons. 
DES Sons’ International Network 
c/o Scott Kerlin, Ph.D. 
1611 Clawthorpe Avenue 
Victoria, British Columbia, Canada  V8T 2R9 
Phone:  250-595-6173 
E-mail: scott@kerlins.net 
or 
Wayne Beyer, M.D. 
8 East Irving Street 
Chevy Chase, MD 20815-4221 
E-mail: wbb3@cornell.edu 
Web site:  
http://groups.yahoo.com/group/des-sons 
DES Sons’ International Network is a private 
online professional health information and sup­
port network for DES Sons and for others 





Centers for Disease Control and Prevention 
(CDC) 
National Breast and Cervical Cancer Early 
Detection Program 
Phone:  (toll-free) 1-888-842-6355 
Web site: 
www.cdc.gov/cancer/nbccedp/index.htm 
The National Breast and Cervical Cancer Early 
Detection Program provides information regard­
ing obtaining free or low-cost mammograms or 
Pap tests; the program also provides information 
about risks for and early detection of breast and 
cervical cancers. 
CDC’s Reproductive Health Information 
Source 
Assisted Reproductive Technology Success Rates, 
National Summary and Fertility Clinic Reports 
Web site:  www.cdc.gov/nccdphp/drh/ 
This Web site contains the annual reports of the 
success rates of assisted reproductive technology, 
as well as information on reproductive health 
issues. 
National Institutes of Health 
National Cancer Institute’s Cancer 
Information Service (CIS) 
Phone:  (toll-free) 1-800-4-CANCER 
(1-800-422-6237) 
TTY Line:  1-800-332-8615 
Web site:  www.cancer.gov or 
http://cis.nci.nih.gov/fact/3_4.htm 
CIS is a service providing accurate, up-to-date 
information on cancer and related issues 
(including DES) to patients and their families, 
health professionals, and the general public.  
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National Institute on Aging (NIA) 
31 Center Drive 
Room 5C27 
Bethesda, MD  20892 
Phone:  301-496-1752 
Web site:  www.nia.nih.gov 
NIA conducts research about aging and provides 
health information to the public on issues relat­
ed to this topic, including menopause, hormone 
replacement therapy, and osteoporosis. 
National Institute of Environmental Health 
Sciences (NIEHS) 
P.O. Box 12233 
Research Triangle Park, NC  27709 
Phone:  919-541-3345 
Web site:  www.niehs.nih.gov 
NIEHS defines how environmental exposures, 
genetic susceptibility, and age interact to affect a 
person’s health.  The Web site contains informa­
tion on DES studies among animals and 
research findings. 
National Heart, Lung, and Blood Institute 
(NHLBI) 
“Facts about HRT and Heart Disease: 
The PEPI Trial” 
31 Center Drive 
MSC 2480, Room 4A10 
Bethesda, MD  20892 
Phone:  301-496-4236 
E-mail: NHLBIinfo@rover.nhlbi.nih.gov 
Web site:  www.nhlbi.nih.gov 
You can order a copy of this publication about 
hormone replacement therapy (HRT) and heart 
disease, by phone, through the Web site, or by 
e-mail. 
Centers for Medicaid and Medicare Services 
(CMS) 
“Your Medicare Benefits”
“Women with Medicare – Visiting Your Doctor 
for a Pap Test, Pelvic Exam, and Clinical Breast 
Exam” 
“Medicare Preventive Services to Keep You 
Healthy” 
Phone:  410-786-3000 
Web site:  www.medicare.gov 
This Web site includes publications that explain 
Medicare’s coverage of routine health screenings, 
as well as additional tests or procedures. 
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Source: The National Cancer Institute (www.cancer.gov/dictionary) 
Adenocarcinoma A cancer that begins in cells 
that line certain internal organs and that have 
glandular (secretory) properties. 
Adenosis Any disease of a gland or abnormal 
development of a gland.  See also “vaginal 
adenosis.” 
Androgens A family of hormones that promote 
the development and maintenance of male sex 
characteristics. 
Autoimmune Disease A condition in which the 
body recognizes its own tissues as foreign and 
directs an immune response against them. 
Examples include multiple sclerosis, rheumatoid 
arthritis, lupus, and diabetes mellitus. 
Benign Not cancerous; does not invade nearby 
tissue or spread to other parts of the body. 
Benign Prostatic Hyperplasia (BPH) A benign 
(non-cancerous) condition in which an over­
growth of prostate tissue pushes against the ure­
thra and the bladder, blocking the flow of urine. 
Also called benign prostatic hypertrophy. 
Biopsy The removal of cells or tissues for exam­
ination under a microscope.  When only a sam­
ple of tissue is removed, the procedure is called 
an incisional biopsy or core biopsy.  When an 
entire lump or suspicious area is removed, the 
procedure is called an excisional biopsy.  When a 
sample of tissue or fluid is removed with a nee­
dle, the procedure is called a needle biopsy or 
fine-needle aspiration. When a cone-shaped 
piece of tissue from the cervix and cervical canal 
is removed in a surgical procedure, it is called a 
cone biopsy or conization. Cone biopsy may be 
used to diagnose or treat a cervical condition. 
British Randomized Trial A group assembled 
to study DES-related health effects.  Participants 
included women exposed to DES during preg­
nancy and men and women exposed before birth 
(in the womb). The DES-exposed group includ­
ed 379 mothers, 144 daughters, and 177 sons. 
A control group of unexposed people included 
371 mothers, 170 daughters, and 163 sons. 
British Research Medical Council (BRMC) 
Study Participants include pregnant diabetic 
women enrolled in clinical trial and DES 
Daughters and DES Sons identified through fol­
low-up study.  Total number of participants is 
151 (79 DES-exposed and 72 unexposed). 
Cancer A term for diseases in which abnormal 
cells divide without control.  Cancer cells can 
invade nearby tissues and can spread through the 
bloodstream and lymphatic system to other parts 
of the body. 
Cancer Information Service (CIS) CIS, part of 
the National Cancer Institute, is the federal gov­
ernment’s principal resource for public informa­
tion about cancer.  CIS interprets and explains 
research findings in a clear and understandable 
manner and provides personalized responses to 
specific questions about cancer.  Access CIS by 
calling 1-800-4-CANCER (1-800-422-6237) or 
by visiting the Web site at http://cis.nci.nih.gov.
Carcinoma Cancer that begins in the skin or in 
tissues that line or cover internal organs. 
Carcinoma In Situ Cancer that involves only 
the cells in which it began and has not spread to 
nearby tissues. 
Carcinosarcoma A malignant (cancerous) 
tumor that is a mixture of carcinoma (cancer of 
epithelial tissue, which is skin and tissue that 
lines or covers the internal organs) and sarcoma 
(cancer of connective tissue, such as bone, carti­
lage, and fat). 
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Cervical Relating to the neck, or the neck of 
any organ or structure.  The cervix is the lower, 
narrow end (or neck) of the uterus. 
Cervical Cancer Refers to cancer of the uterine 
cervix.  Routine screening for cervical cancer 
with Papanicolaou (Pap) testing is recommended 
for all women who are or have been sexually 
active and who have a cervix. 
Cervical Intraepithelial Neoplasia (CIN) A 
general term for the growth of abnormal cells on 
the surface of the cervix. 
Cervix The lower, narrow end of the uterus that 
forms a canal between the uterus and vagina. 
Clear Cell Adenocarcinoma (CCA) 
Clear Cell Carcinoma A rare type of tumor of 
the female genital tract in which the inside of the 
cells look clear when viewed under a microscope. 
Adenocarcinoma A cancer that begins in cells 
that line certain internal organs and that have 
glandular (secretory) properties. 
Clinical Breast Examination An examination 
by a medical professional during which the 
breasts are palpated (or lightly felt) with the 
hand and fingers to determine the condition 
underneath. Breast appearance is checked for 
dimpling, rashes, and nipple discharge. 
Cohort A group of people sharing common 
characteristics or experiences, often followed by a 
research study over long periods of time.  By 
compiling and summarizing data from a cohort, 
scientists can observe whether disease conditions 
develop at higher rates in a cohort group than 
they would expect in the general population. 
The DES Combined Cohort Study (DCCS) is 
an example of research using a cohort. 
Colposcopy Examination of the vagina and 
cervix using a lighted magnifying instrument 
called a colposcope. 
Complete Hysterectomy A surgical procedure 
to remove the entire uterus, including the cervix. 
Also called total hysterectomy. 
Connecticut Mothers Study A group assem­
bled as participants in DES-related research. 
The participants included women who delivered 
babies during 1946–1965, at medical offices in 
Fairfield and New Haven Counties, 
Connecticut. The participants included 1,706 
DES-exposed mothers, and 1,405 unexposed 
mothers. The participants are now included in 
the DES Combined Cohort Studies.  
Corticosteroids Steroid-type hormones that 
have antitumor activity in lymphomas and lym­
phoid leukemias. In addition, corticosteroids 
may be used for hormone replacement and for 
the management of some of the complications of 
cancer and its treatment. 
Cortisone A natural steroid hormone produced 
in the adrenal gland.  It can also be made in the 
laboratory.  Cortisone reduces swelling and can 
suppress immune responses. 
Cryptorchidism A condition in which one or 
both testicles fail to move from the abdomen, 
where they develop before birth, into the scro­
tum. Also called undescended testicles. 
Dieckmann Cohort A group assembled in 
1974 to study DES-related health risks. 
Participants included approximately 800 women 
exposed to DES while pregnant and 800 unex­
posed mothers; approximately 400 women 
exposed to DES before birth (in the womb) and 
400 women in a control group; and approxi­
mately 400 men exposed to DES before birth 
and 400 unexposed men. The 1974 group rep­
resented the second Dieckmann cohort.  The 
first included mothers who were participants in a 
study at the University of Chicago in the early 
1950s. Results based on the initial study indi­
cated that DES was not effective in preventing 
miscarriages. 
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Diethylstilbestrol (DES) A synthetic estrogen 
that was developed in 1938 to supplement a 
woman’s natural estrogen production.  DES was 
prescribed by doctors for women who experi­
enced miscarriages or premature deliveries.  DES 
was originally considered effective and safe for 
both the pregnant woman and the developing 
baby.  In the United States, an estimated 5–10 
million persons were exposed to DES during 
1938–1971. Since 1971, DES has been linked 
to an increased risk of clear cell adeno carcinoma 
of the vagina and cervix, infertility, and pregnan­
cy complications in women exposed to DES 
before birth (in the womb), known as DES 
Daughters.  In addition, women who were pre­
scribed DES while pregnant are at a modestly 
increased risk for breast cancer.  Men exposed to 
DES before birth (in the womb), known as DES 
Sons, are at an increased risk for non-cancerous 
epididymal cysts. 
Diethystilbestrol Adenosis Project (DESAD) 
The DESAD began in 1974 at Baylor College of 
Medicine, Gundersen Clinic, Massachusetts 
General Hospital, the Mayo Clinic, and the 
University of Southern California.  The DESAD, 
the largest DES cohort, included 4,014 DES 
Daughters (women exposed to DES before 
birth) and 1,033 unexposed women.  Exposed 
women had documented evidence of DES expo­
sure through review of prenatal records or 
through physician referral.  The DESAD was 
assembled to conduct studies to determine if 
DES Daughters were at an increased risk of 
health problems related to their DES exposure. 
DES Combined Cohort Studies (DCCS) 
The DCCS combines previously established 
DES study group participants (cohorts).  The 
combined groups include approximately 5,000 
women exposed to DES during pregnancy and 
4,000 unexposed mothers; 5,000 exposed and 
2,500 unexposed daughters; and 2,000 exposed 
and 2,000 unexposed sons. The goal of the 
DCCS is to determine whether the risk for can­
cer among DES-exposed persons is increased as a 
result of exposure to DES.  Other health out­
comes (such as infertility and pregnancy out­
comes) also are being investigated through the 
DCCS. 
DES Mothers Study The DES Mothers Study 
began in 1980. The participant group (cohort) 
included approximately 3,000 women exposed 
to DES while pregnant and 3,000 unexposed 
women. These participants had delivered babies 
during 1940–1960 at Boston Lying-In Hospital, 
the Mayo Clinic, Dartmouth Medical School, 
and a private practice in Portland, Maine. 
Exposure status was determined through review 
of medical records.  The cohort was created as a 
means to determine if women exposed to DES 
during pregnancy were at increased risk for 
cancer.  
Dose-dependent Refers to the effects of treat­
ment with a drug.  If the effects change when 
the dose of the drug is changed, the effects are 
said to be dose-dependent. 
Dysplasia Cells that look abnormal under a 
microscope but are not cancer. 
Ectopic Pregnancy A pregnancy outside the 
uterus, typically in a fallopian tube. 
Embryo Early stage in the development of a 
plant or an animal. In vertebrate animals (those 
that have a backbone or spinal column), this 
stage lasts from shortly after fertilization until all 
major body parts appear.  In humans, this stage 
lasts from about 2 weeks after fertilization until 
the end of the eighth week of pregnancy. 
Endocrine Therapy Treatment that adds, 
blocks, or removes hormones.  For certain condi­
tions (such as diabetes or menopause) hormones 
are given to adjust low hormone levels.  To slow 
or stop the growth of certain cancers (such as 
prostate and breast cancer) hormones may be 
given to block the body’s natural hormones. 
Sometimes surgery is needed to remove the 
source of hormones.  Also called hormone thera­
py, hormonal therapy, and hormone treatment. 
Endocrinologist A doctor who specializes in 
diagnosing and treating hormone disorders. 
Endometriosis A noncancerous (benign) condi­
tion that occurs when tissue that looks like 
endometrial (uterine) tissue grows in abnormal 
places in the abdomen. 
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Endometrium The layer of tissue that lines the 
uterus (womb). 
Epididymal Cyst A benign (non-cancerous) sac 
or capsule on the testes. 
Epididymis A cord-like structure along the 
back border of each testis.  Sperm matures and is 
stored in the coiled duct that runs through this 
structure. 
Epithelial Refers to the cells that line the inter­
nal and external surfaces of the body.        
Epithelium A thin layer of tissue that covers 
organs, glands, and other structures within the 
body. 
Estradiol The most potent naturally occurring 
estrogen in humans. 
Estrogen Replacement Therapy (ERT) 
Estrogen given to postmenopausal women or to 
women who have had their ovaries surgically 
removed.  Hormones are given to replace the 
estrogen no longer produced by the ovaries. 
Estrogens A family of hormones that promote 
the development and maintenance of female sex 
characteristics. Estrogen is a generic term for 
estrus-producing compounds (female sex hor­
mones) including estradiol, estriol, and estrone. 
Etiology The cause or origin of disease. 
Excisional Biopsy A surgical procedure in 
which an entire lump or suspicious area of tissue 
is removed for diagnosis.  The tissue is then 
examined under a microscope. 
Fallopian Tubes Part of the female reproductive 
tract; the long slender tubes through which eggs 
pass from the ovaries to the uterus. 
Fetus A developing unborn offspring in the 
uterus (womb).  This stage of pregnancy begins 
8 weeks after conception and lasts until birth. 
Fibroid A non-cancerous (benign) smooth-mus­
cle tumor, usually in the uterus (womb) or diges­
tive (gastrointestinal) tract.  Also called leiomy­
oma. 
Fine-needle Aspiration The removal of tissue 
or fluid with a needle for examination under a 
microscope.  Also called needle biopsy. 
Focal In terms of cancer, limited to a specific 
area. 
Follow-up Monitoring an person’s health over 
time after treatment.  This includes keeping 
track of the health of people who participate in a 
clinical study or clinical trial for a period of time, 
both during and after the study ends. 
Food and Drug Administration (FDA) FDA, 
part of the United States Department of Health 
and Human Services, is the federal government’s 
principal agency to promote and protect the 
public health by helping safe and effective prod­
ucts reach the market in a timely way and by 
monitoring products for continued safety after 
they are in use.  In 1971, the FDA issued a Drug 
Bulletin advising physicians to stop prescribing 
DES to pregnant women because it was linked 
to a rare vaginal cancer in female offspring.  The 
bulletin is titled FDA Drug Bulletin: 
Diethylstilbestrol Contraindicated in Pregnancy. 
Washington, DC: U.S. Department of Health, 
Education and Welfare (DHEW), 1971.  You 
can access the FDA’s Web site at www.fda.gov. 
Gene The functional and physical unit of 
heredity passed from parent to offspring.  Genes 
are pieces of DNA, and most genes contain the 
information for making a specific protein. 
Gland An organ that produces and releases one 
or more substances for use in the body.  Some 
glands produce fluids that affect tissues or 
organs. Others glands produce hormones. 
Glucocorticoid A substance that belongs to the 
family of compounds called corticosteroids 
(steroids).  Glucocorticoids affect metabolism 
(chemical and physical changes in living cells). 
In addition glucocorticoids and have anti-inflam­
matory and immunosuppressive effects.  They 
may be naturally produced (hormones) or syn­
thetic (drugs).       
Gonads The part of the reproductive system 
that produces and releases eggs in females 
(ovaries) and sperm  in males (testicles/testes). 
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Grade When referring to a tumor, the grade 
indicates the level of abnormality found in the 
cancer cells when viewed through a microscope 
and how quickly the tumor is likely to grow and 
spread.  Grading systems vary for each type of 
cancer. 
Gynecologic Having to do with the female 
reproductive tract (including the cervix, 
endometrium, fallopian tubes, ovaries, uterus, 
and vagina). 
Gynecologic Cancer Cancer of the female 
reproductive tract, including the cervix, 
endometrium, fallopian tubes, ovaries, uterus, 
and vagina. 
Gynecologic Oncologist A doctor who special­
izes in treating cancers of the female reproductive 
organs. 
Gynecologist A doctor who specializes in health 
conditions and problems related to the female 
reproductive organs. 
Half-life The time required for half the amount 
of a substance (such as a drug or radioactive sub­
stance) in a living system (body tissue) or ecosys­
tem to be eliminated or disintegrated by natural 
processes (decay or biological elimination). 
High-grade Squamous Intraepithelial Lesion 
(HSIL) A pre-cancerous condition in which the 
cells of the uterine cervix are moderately or 
severely abnormal.  Not all HSILs become can­
cerous, even if left untreated. 
Hysterosalpingogram An X-ray that can check 
for differences and physical alterations in the 
female upper genital tract. 
Hormonal Therapy Treatment that adds, 
blocks, or removes hormones.  For certain condi­
tions (such as diabetes or menopause), hormones 
are given to adjust low hormone levels.  To slow 
or stop the growth of certain cancers (such as 
prostate and breast cancer), hormones may be 
given to block the body’s natural hormones. 
Sometimes surgery is needed to remove the 
source of hormones.  Also called hormone thera­
py, hormone treatment, hormone replacement 
therapy, or endocrine therapy. 
Hormone Chemicals produced by glands in the 
body and circulated in the bloodstream. 
Hormones control the actions of certain cells or 
organs. 
Hormone Replacement Therapy (HRT) 
Hormones (estrogen, progesterone, or both) 
given to postmenopausal women or women who 
have had their ovaries surgically removed to 
replace the estrogen no longer produced by the 
ovaries. 
Hyperplasia An abnormal increase in the num­
ber of cells in an organ or tissue. 
Hypospadias A developmental abnormality in 
males in which the urethra (opening of the 
penis) is misplaced on the underside of the 
penis. 
Hysterectomy An operation in which the 
uterus is removed. 
Immune System The complex group of organs 
and cells that defends the body against infection 
and disease. 
Incidence The number of new cases of a disease 
diagnosed each year. 
Incisional Biopsy A surgical procedure in 
which a portion of a lump or suspicious area of 
tissue is removed for diagnosis.  The tissue is 
then examined under a microscope. 
Infertility The inability to produce children. 
Inflammatory Breast Cancer A type of breast 
cancer in which the breast looks red and swollen 
and feels warm. The skin of the breast may also 
show the pitted appearance called peau d’orange 
(like the skin of an orange). The redness and 
warmth occur because the cancer cells block the 
lymph vessels in the skin. 
In Situ Cancer Early cancer that has not spread 
to neighboring tissue. 





[ 6 ] DES GLOSSARY 
Institutional Review Board (IRB) A group 
that may include scientists, physicians, clergy, 
and consumers at agencies and other facilities 
that participates in clinical trials.  IRBs are 
designed to protect research participants.  They 
review and must approve the action plan for 
every clinical trial.  They check to see that the 
trial is well designed, does not involve undue 
risks, and includes safeguards for research partici­
pants. 
Invasive Cervical Cancer Cancer that has 
spread from the surface of the cervix to tissue 
deeper in the cervix or to other parts of the 
body. 
Laboratory Study Research done in a laborato­
ry.  These studies may use test tubes or animals 
to find out if a drug, procedure, or treatment is 
likely to be useful. Laboratory studies take place 
before testing is done in humans. 
Laboratory Test A medical procedure that 
involves testing a sample of blood, urine, or 
other substance from the body.  These tests can 
help determine a diagnosis, plan treatment, 
check to see if treatment is working, or monitor 
a disease over time. 
Lesion An area of abnormal tissue change. 
Leuprolide A drug that belongs to a family of 
drugs called gonadotropin-releasing hormone 
analogues. It is used to block hormone produc­
tion in the ovaries or testicles. 
Lupus A chronic inflammatory connective tis­
sue disease marked by skin rashes, joint pain and 
swelling, inflammation of the kidneys, inflam­
mation of the fibrous tissue surrounding the 
heart, and other problems.  Not all affected per­
sons have all of these problems.  Also called sys­
temic lupus erythematosus. 
Lutenizing Hormone-Releasing Hormone 
(LH-RH) A hormone that stimulates the pro­
duction of sex hormones in men and women. 
Lutenizing Hormone-Releasing Hormone 
(LH-RH) Agonist A drug that inhibits the 
secretion of sex hormones.  In men, LH-RH 
agonist causes testosterone levels to fall.  In 
women, LH-RH agonist causes the levels of 
estrogen and other sex hormones to fall. 
Lymph Gland A rounded mass of lymphatic 
tissue that is surrounded by a capsule of connec­
tive tissue.  Lymph glands are spread out along 
lymphatic vessels and contain many lympho­
cytes, which filter the lymphatic (lymph) fluid. 
Malignant Cancerous; a growth with a tenden­
cy to invade and destroy nearby tissue and 
spread to other parts of the body. 
Mammogram An X-ray of the breast. 
Mayo Clinic Sons Study The Sons Study 
included approximately 800 men exposed to 
DES before birth (in the womb) and 600 unex­
posed men. This cohort was identified by review 
of medical records of women who gave birth at 
Mayo Clinic hospitals. 
Menopause The time of life when a woman’s 
menstrual periods stop permanently.  Also called 
change of life. 
Menstrual Cycle The monthly cycle of a 
woman’s hormonal changes from the beginning 
of one menstrual period to the beginning of the 
next. 
Menstruation Periodic discharge of blood and 
tissue from the uterus (womb).  Until 
menopause, menstruation occurs approximately 
every 28 days when a woman is not pregnant. 
Microphallus A smaller than normal penis. 
Miscarriage When a fetus leaves the uterus 
before the fifth month of pregnancy. 
Myometrium The muscular outer layer of the 
uterus. 
National Cancer Institute (NCI) Part of the 
National Institutes of Health of the United 
States Department of Health and Human 
Services.  NCI is the federal government’s princi­
pal agency for cancer research.  NCI conducts, 
coordinates, and funds cancer research, training, 
health information dissemination, and other pro­
grams regarding the cause, diagnosis, prevention, 
and treatment of cancer.  Access the NCI Web 
site at www.cancer.gov.
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National Institutes of Health (NIH) Part of 
the United States Department of Health and 
Human Services.  NIH is the federal govern­
ment’s principal agency for biomedical research. 
NIH conducts research in its own laboratories; 
supports the research of non-federal scientists in 
universities, medical schools, hospitals, and 
research institutions throughout the country and 
abroad; helps in the training of research investi­
gators; and fosters communication of medical 
information. Access the NIH Web site at 
www.nih.gov.
Neuroendocrine Having to do with the interac­
tions between the nervous system and the 
endocrine system. Certain cells release hor­
mones into the blood in response to stimulation 
of the nervous system. 
Nonmalignant Not cancerous. 
Observation Closely monitoring a patient’s 
condition without treatment until symptoms 
appear or change. Also called watchful waiting. 
Oncogene A gene that normally directs cell 
growth.  If altered, an oncogene can promote or 
allow the uncontrolled growth of cancer. 
Alterations can be inherited or caused by an 
environmental exposure to carcinogens. 
Oncologist A doctor who specializes in treating 
cancer.  Some oncologists specialize in a particu­
lar type of cancer treatment.  For example, a 
radiation oncologist specializes in treating cancer 
with radiation. 
Oophorectomy A surgical procedure to remove 
one or both ovaries. 
Orchiectomy A surgical procedure to remove 
one or both testicles. 
Osteoporosis A condition that is characterized 
by a decrease in bone mass and density and caus­
es bones to become fragile. 
Ovarian Suppression A surgical procedure, 
radiation therapy, or a drug treatment to stop the 
functioning of the ovaries.  Also called ovarian 
ablation. 
Ovaries The pair of female reproductive glands 
in which the eggs (ova) are formed.  The ovaries 
are located in the pelvis, one on each side of the 
uterus (womb). 
Ovulation The release of an egg from an ovary 
during the menstrual cycle. 
Pap Smear The collection of cells from the 
cervix for examination under a microscope.  Pap 
smears are used to detect changes that may be 
cancer or may lead to cancer (pre-cancerous) and 
can detect non-cancerous conditions (such as 
infection or inflammation). Also called a Pap 
test. 
Patient Advocate A person who helps a patient 
work with others who have an effect on the 
patient’s health, including doctors, insurance 
companies, employers, case managers, and 
lawyers.  A patient advocate helps resolve issues 
about health care, medical bills, and job discrim­
ination related to a patient’s medical condition. 
Patient advocacy groups try to raise public 
awareness about important health issues (such as 
the need for support services, education, and 
research).  Such groups work to bring about 
change that will help patients and their families. 
Pelvic Having to do with the pelvis (the lower 
part of the abdomen located between the hip 
bones). 
Perimenopausal The time in a woman’s life 
when menstrual periods become irregular. 
Refers to the time near menopause. 
Pilot Study The initial study examining a new 
method or treatment. 
Placenta The organ that nourishes the develop­
ing fetus in the uterus. 
Postmenopausal The time in a woman’s life 
after menopause. 
Pre-cancerous A term used to describe a condi­
tion that might or is likely to become cancer. 
Also called premalignant. 
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Premenopausal The time in a woman’s life 
before menopause. 
Prescription A doctor’s order for medicine or 
another treatment. 
Primary Care Physician A doctor who man­
ages a person’s health care over time.  A primary 
care physician can provide a wide range of care 
(including prevention and treatment) can discuss 
treatment choices, and can refer a patient to a 
specialist. 
Progesterone A female hormone. 
Progesterone Receptor Negative (PR-) Breast 
cancer cells that do not have a protein (receptor 
molecule) to which progesterone will attach. 
Breast cancer cells that are PR- do not need the 
hormone progesterone to grow and usually do 
not respond to hormonal therapy. 
Progesterone Receptor Positive (PR+) Breast 
cancer cells that have a protein (receptor mole­
cule) to which progesterone will attach.  Breast 
cancer cells that are PR+ need the hormone 
progesterone to grow and will usually respond to 
hormonal therapy. 
Prospective A research study or clinical trial in 
which participants are identified and then fol­
lowed over time. 
Prostate A gland in the male reproductive sys­
tem just below the bladder.  The prostate sur­
rounds part of the urethra, the canal that emp­
ties the bladder, and produces a fluid that forms 
part of semen. 
Prostate-Specific Antigen (PSA) A substance 
produced by the prostate that may be found in 
an increased amount in the blood of men who 
have prostate cancer, benign prostatic hyperpla­
sia, or infection or inflammation of the prostate.  
p-value A term used in statistics. A p-value 
expresses statistical significance in scientific stud­
ies. P-values are calculated using a statistical for­
mula that includes the number of people and 
health effects being studied. It is designed to 
answer the question, “Could a group of this 
many people, who all experienced a common 
exposure, have had this health problem in com­
mon by chance alone?”  It is standard practice to 
consider a finding statistically significant if there 
is less than a 5% probability (p=.05 or less) that 
the findings resulted from chance.  Conversely, if 
there is greater than a 5% probability (p=.06 or 
greater) that a finding was due to chance, the 
finding is not statistically significant. 
Raloxifene A drug that belongs to the family of 
drugs called selective estrogen receptor modula­
tors (SERMs) and is used in the prevention of 
osteoporosis in postmenopausal women. 
Raloxifene is also being studied as a cancer-pre­
vention drug. 
Receptor A molecule inside or on the surface of 
a cell that binds to a specific substance and caus­
es a specific physiologic effect in the cell. 
Registry for Research on Hormonal 
Transplacental Carcinogenesis The Registry 
was established at Massachusetts General 
Hospital in 1971 to track incidence of clear cell 
adenocarcinoma (CCA) of the vagina or cervix. 
Originally numbering 21 cases, by 2002 approxi­
mately 750 cases were recorded at the registry. 
Most of the information on treatment outcome 
and recurrence rates of CCA has come from the 
study of patients in the Registry. The registry is 
now located at the University of Chicago 
(Department of Obstetrics and Gynecology, The 
University of Chicago, 5841 South Maryland 
Avenue, Mail Code 2050, Chicago, IL, 60637. 
Phone: 773-702-6671.  Fax: 773-702-5161). 
Reproductive Cells Egg and sperm cells.  Each 
mature reproductive cell carries a single set of 23 
chromosomes. 
CDC’s DES Update Toll-free 1-888-232-6789 www.cdc.gov/DES 
 
 
DES GLOSSARY [ 9 ] 
Reproductive System In women, this system 
includes the ovaries, fallopian tubes, uterus 
(womb), cervix, and vagina (birth canal).  The 
reproductive system in men includes the 
prostate,  testes, and penis. 
Retrospective Study A study that looks back­
ward in time, usually using medical records and 
interviews with patients who already have or had 
a disease. 
Risk Factor Anything that increases a person’s 
chance of developing a disease, including a sub­
stance, agent, genetic alteration, trait, habit, or 
condition. 
Salpingo-Oophorectomy A surgical procedure 
to remove the fallopian tubes and ovaries. 
Sarcoma A cancer of the bone, cartilage, fat, 
muscle, blood vessels, or other connective or 
supportive tissue. 
Scrotum In males, the external sac that contains 
the testicles. 
Selective Estrogen Receptor Modulator 
(SERM) A drug that acts like estrogen on some 
tissues but blocks the effect of estrogen on other 
tissues. Tamoxifen and raloxifene are SERMs. 
Semen The fluid that is released through the 
penis during orgasm. Semen is made up of 
sperm from the testicles and fluid from the 
prostate and other sex glands. 
Seminal Fluid The fluid from the prostate and 
other sex glands that helps transport sperm out 
of the man’s body during orgasm.  Seminal fluid 
contains sugar as an energy source for sperm. 
Seminal Vesicles Glands that help produce 
semen. 
Side Effects Problems that occur when treat­
ment affects healthy cells. For example, com­
mon side effects of cancer treatment are fatigue, 
nausea, vomiting, decreased blood cell counts, 
hair loss, and mouth sores. 
Speculum An instrument used to widen an 
opening of the body to make it easier to look 
inside. 
Squamous Cell Carcinoma Cancer that begins 
in squamous cells, which are thin, flat cells 
resembling fish scales.  Squamous cells are found 
in the tissue that forms the surface of the skin, 
the lining of the hollow organs of the body, and 
the passages of the respiratory and digestive 
tracts. Also called epidermoid carcinoma. 
Squamous Cells Flat cells that look like fish 
scales under a microscope.  These cells cover 
internal and external surfaces of the body. 
Squamous Intraepithelial Lesion (SIL) A gen­
eral term for the abnormal growth of squamous 
cells on the surface of the cervix.  The changes in 
the cells are described as low grade or high grade, 
depending on how much of the cervix is affected 
and how abnormal the cells appear. 
Statistically Significant A statistical concept 
used to determine causal links or associations in 
scientific studies. Statistical significance is 
expressed in scientific studies by a probability 
value (p-value).  P-values are calculated using a 
statistical formula that includes the number of 
people and health effects being studied and is 
designed to answer the question, “Could a group 
of this many people, who all experienced a com­
mon exposure, have had this health problem in 
common by chance alone?”  It is standard prac­
tice to consider a finding statistically significant 
if there is less than a 5% probability (p=.05 or 
less) that the findings resulted from chance. 
Conversely, if there is greater than a 5% proba­
bility (p=.06 or greater) that a finding was due to 
chance, the finding is not statistically significant. 
T-shaped Uterus A structural malformation in 
which the uterus resembles the letter “T” rather 
than the letter “U.” 
Tamoxifen An anticancer drug that belongs to 
the family of drugs called antiestrogens. 
Tamoxifen blocks the effects of the hormone 
estrogen in the body.  It is used to prevent or 
delay the return of breast cancer or to control its 
spread. 
Testosterone A hormone that promotes the 
development and maintenance of male sex char­
acteristics. 
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Third Generation The offspring (children) of 
DES Daughters or Sons.  Also called DES 
Grandchildren. 
Total Hysterectomy Surgery to remove the 
entire uterus, including the cervix.  Also called 
complete hysterectomy. 
Tubal Ligation An operation to tie the fallopi­
an tubes closed. This procedure prevents preg­
nancy by blocking the passage of eggs (ova) 
from the ovaries to the uterus (womb). 
Undescended Testicles A condition in which 
one or both testicles fail to move from the 
abdomen, where they develop before birth, into 
the scrotum.  Also called cryptorchidism. 
Urologist A physician who specializes in dis­
eases of the urinary organs in females and the 
urinary and sex organs in males. 
Uterus The small, hollow, pear-shaped organ in 
a woman’s pelvis.  This is the organ in which a 
fetus develops.  Also called the womb. 
Vagina The muscular canal extending from the 
uterus to the exterior of the body.  Also called 
the birth canal. 
Vaginal Adenosis Cellular changes on the sur­
face of the vagina.  Adenosis is a type of tissue 
on the surface of the vagina that is usually not 
found on the vagina.  Vaginal adenosis is benign 
(non-cancerous).  Over time, vaginal adenosis is 
usually replaced by normal tissue.  Monitoring 
adenosis is recommended, but no treatment is 
necessary.
Vulva The external female genital organs, 
including the clitoris, vaginal lips, and the open­
ing to the vagina. 
Womb The small, hollow, pear-shaped organ in 
a woman’s pelvis.  This is the organ in which a 
fetus develops.  Also called the uterus. 
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Overview 
Much has been written about the health risks of DES exposure and other topics related to DES.  
To  help you find more information about a specific topic or study, a list of published research and 
other sources of DES is included below.  The list is organized by main topic.  This section of 
CDC’s DES Update includes a bibliography organized by the following topics. 
• History 
• Women Prescribed DES While Pregnant 
• Women Exposed to DES Before Birth (In the Womb), Known as DES Daughters 
✦ Structural/Functional Differences 
✦ Fertility 
✦ Clear Cell Adenocarcinoma (CCA) 
✦ Other Cancer 
• Men Exposed to DES Before Birth (In the Womb), Known as DES Sons 
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Diethylstilbestrol (DES) is a synthetic estrogen that was developed to supplement 
a woman’s natural estrogen production. First prescribed by physicians in 1938 for 
women who experienced miscarriages or premature deliveries, DES was originally 
considered effective and safe for both the pregnant woman and the developing 
baby.  In the United States, an estimated 5—10 million persons were exposed to 
DES during 1938—1971, including women who were prescribed DES while pregnant 
and the female and male children born of these pregnancies.  In 1971, the Food 
and Drug Administration (FDA) issued a Drug Bulletin advising physicians to stop 
prescribing DES to pregnant women because it was linked to a rare vaginal cancer 
in female offspring. 
Is There a Medical Test for DES Exposure? 
No known medical test (such as blood, urine or skin analysis) has been developed 
that can detect DES exposure.  However, the DES Self-Assessment Guide is 
designed to help you assess whether you might have been exposed to DES. 
Who Should Use the DES Self-Assessment Guide? 
• Women pregnant between 1938 and 1971  
• Women born between 1938 and 1971  
• Men born between 1938 and 1971 
Note: Women who were BOTH born AND pregnant during 1938—1971 should respond to the 
statements for both women who were pregnant and women who were born during 1938—1971. 
This self-assessment is part of the Centers for Disease Control and Prevention’s DES 
Update — information for you, your family, and your health care provider. 




Known Health Risks of DES Exposure 
More than 30 years of research have confirmed that health risks are associated with DES 
exposure. However, not all exposed persons will experience DES-related health problems. 
Research published 1971—2002 linked DES exposure 
with increased health risks: 
WOMEN PRESCRIBED DES WHILE PREGNANT. These women are at a modestly 
increased risk for 
• Breast cancer 
WOMEN EXPOSED TO DES BEFORE BIRTH (in the womb), known as DES Daughters, 
are at an increased risk for 
• Clear cell adenocarcinoma (CCA) of the vagina and cervix  
• Reproductive tract structural differences 
• Pregnancy complications 
• Infertility 
MEN EXPOSED TO DES BEFORE BIRTH (in the womb), known as DES Sons, are at 
an increased risk for 
• Non-cancerous epididymal cysts 
What Does the Term “Increased Health Risk” Mean? 
 
Increased risk means that the women and men who were exposed to DES are more likely to 
have certain health problems than people who were not exposed. 
The Self-Assessment will guide you through 4 Steps. Please turn the page for Step 1. 
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DES Self-Assessment Step 1 
How Do I Use the Self-Assessment?


The Self-Assessment has 4 Steps. Start with Step 1 on this page. 
• Read each numbered statement. 
• Mark your personal responses: Yes/Not Sure (NS), No/Not Applicable (NA) 
• Follow directions in the section, “What do my responses mean?” at the bottom of each page. 
1. When I was pregnant,* I had regular medical care. . . . . . . . .  Yes/NS  No/NA 
2. When my mother was pregnant with me,* 
 
she had regular medical care.  . . . . . . . . . . . . . . . . . . . . . . . . .  Yes/NS  No/NA
 

3. I was prescribed DES when I was pregnant.*  . . . . . . . . . . .  Yes/NS  No/NA 
4. When my mother was pregnant with me,* 
 




How Was DES Given to Pregnant Women? 
Women who obtained DES were required to have a physician’s prescription filled by a pharma­
cist, although some physicians gave DES directly to their patients. Therefore, women who were 
not under a physician’s care during their pregnancy most likely did not receive the drug. 
Note: DES is sometimes confused with the drug Thalidomide that caused birth defects. 
Thalidomide was never approved for prescription in the United States. DES was called by 
different labels. Some of the most common were stilbestrol and DESPlex. 
WHAT DO MY RESPONSES MEAN? 
If you marked Yes/Not Sure to any of the statements 1—4, continue to STEP 2. 
If you marked No/Not Applicable to all statements 1—4, it is unlikely that you were 
exposed to DES. However, it is still important for you to receive regular health checkups 








DES Self-Assessment Step 2 
All women and men who responded Yes/Not Sure 
to any of the statements 1—4 should continue to respond to statements 5—8. 
5. My mother had at least one miscarriage* 
before I was born.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Yes/NS  No/NA 
6. My mother’s doctor prescribed medication 
to treat or help prevent pregnancy problems 
while she was pregnant with me.*  . . . . . . . . . . . . . . . . . . . .  Yes/NS  No/NA 
7. I had at least one miscarriage.*  . . . . . . . . . . . . . . . . . . . . . .  Yes/NS  No/NA 
8. My doctor prescribed medication while I was 
pregnant* to treat or help prevent pregnancy 
problems.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Yes/NS  No/NA 
*during 1938—1971 
How Did Physicians Decide to Prescribe DES? 
Most women who were prescribed DES had a history of miscarriage and/or giving birth 
prematurely before the pregnancy when they were prescribed DES. DES was prescribed in 
different forms (most commonly as a pill); but it also was given by injection or as a vaginal 
suppository. 
WHAT DO MY RESPONSES MEAN? 
If you marked Yes/Not Sure to any of the statements 5—8, continue to STEP 3. 
If you marked No/Not Applicable to all statements 5—8, it is unlikely that you were 
exposed to DES. However, it is still important for you to receive regular health checkups 
and consult with your health care provider about any potential health problems. 
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